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Abstract
The dynamic Hsp70-90 chaperone machinery along with its cochaperone partners are
well-characterized for their ability to fold, assemble, and regulate steroid hormone receptors
(SHRs). Human small glutamine rich tetratricopeptide repeat (TPR) containing protein alpha
(SGTA) is a recently identified protein that has a characteristic Hsp90-binding TPR domain and
is a key participant in the androgen, glucocorticoid, and progesterone receptor signaling
pathway. In addition, SGTA plays a role in cellular processes such as cell cycle progression and
apoptosis. We have demonstrated that SGTA binds directly to both Hsp70 (kd = 6 µM) and
Hsp90 (kd = 11 µM). In a cell-free system, SGTA is unable to affect chaperone complex
formation and receptor hormone binding. In addition, deletion of the Q-rich region at the Cterminus of SGTA failed to abrogate AR function in yeast reporter assays. To better understand
the functional role of SGTA in SHR regulation, we undertook a label-free quantitative
proteomics approach to determine unknown interacting proteins with SGTA in LNCaP human
prostate cancer cells. Tandem affinity purification followed by Liquid Chromatography Mass
Spectrometry (LC-MS/MS) was performed to identify unknown protein interactions. To
determine if interactions were transient or strong, a comparison of a 3-hour versus an overnight
incubation was used. Our quantitative data suggest that SGTA interacts with proteins involved in
a diverse range of pathways. Peroxiredoxin 1 (PRDX1) was present in both conditions and in the
three biological replicates. PRDX1 is involved in redox regulation of the cell and has antioxidant
properties. In addition, it has been linked to the androgen receptor (AR) pathway where it can
bind to AR and enhance its transactivation. Utilizing SGTA and PRDX1 purified, recombinant
proteins, we performed an in vitro FLAG pull-down assay using proteins alone or in
combination. The in vitro FLAG pull-down assays demonstrated that SGTA directly interacts
with PRDX1. In addition, PRDX1 co-immunoprecipitated with SGTA in LNCaP cells. Thus, we
sought to determine the functional relevance of the SGTA-PRDX1 interaction. We generated
CRISPR/Cas9 SGTAKO HeLa and 22RV1 cell lines and assessed the functional relevance of
viii

SGTA and PRDX1. Using luciferase reporter assays we demonstrated that SGTA can antagonize
PRDX1 potentiation of AR activity suggesting the mechanism for the negative regulation of AR
by SGTA is through competition with PRDX1.
The yeast-based steroid hormone receptor-mediated reporter assay has historically
provided much of the evidence regarding the importance of chaperones and cochaperones in
steroid hormone receptor signaling pathways and was critical for the characterization of SGTA
functional domains in this study. Given our expertise with this system our group modified this
assay previously to a short 4-hour assay for use in screening environmental samples for
estrogenic activity. Because of the short assay time, sterility is not an issue and samples can be
measured directly without extraction or sterilization. As a result, we hypothesized that the assay
could be used for the direct measure of estrogenic activity in urine as a novel research tool as
well. Thus, we sought to validate its application in human urine samples. The ability and
sensitivity of the yeast bioassay to detect estrogenic activity in urine samples from pregnant
females in all trimesters was assessed. No toxicity was observed in yeast grown in the presence
of human pregnant female urine for 2 hours and the assay was able to accurately detect the
increasing estrogenic activity expected with increasing trimester. Upon the addition of βglucoronidase and sulfatase to deconjugate estrogenic metabolites we demonstrated that the
assay sensitivity can be increased significantly (i.e. significantly more estrogenic activity was
detected). Thus, these assays represent a novel research tool to detect estrogenic activity in
animal and human urine samples in a rapid and sensitive manner.
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Chapter 1: Introduction

1

1.1 Androgen Receptor Structure, Function, and Physiological Regulation
Steroid Hormone Receptors (SHRs) are an evolutionary conserved group that belongs to
the nuclear receptor superfamily. The glucocorticoid (GR), androgen (AR), progesterone (PR),
mineralocorticoid (MR), and estrogen (ER) receptors comprise the main SHRs in the nuclear
receptor subfamily 3 category (1-4). Upon hormone binding, SHRs act as transcription factors in
eukaryotes to maintain an array of physiological processes in homeostasis (5). These genomic
actions constitute processes such as development, reproduction, sexual differentiation, energy
metabolism, and electrolyte balance (6).
Steroid hormones utilize cholesterol as the precursor and undergo multiple enzymatic
conversions to adapt an agonist structure that will bind to its respective receptor. Steroid
hormones have tissue specificity and are synthesized in the adrenal cortex (GR and PR), testes
(AR), ovaries (ER), and corpus luteum (PR) (7). Biosynthesis initiates upon desmolase
converting cholesterol to pregnenolone (8). Moreover, 3β-hydroxysteroid dehydrogenase
modifies it to progesterone where 17-hydroxylase converts it to 17-αhydroxyprogesterone and
based on necessity, the enzymatic conversions along with protein interactors will proceed until
they reach their target receptor (8-10). These ligands will bind to the Ligand Binding Domain
(LBD) of the SHR. For instance, testosterone and 5α-DHT are the main ligands for AR; they
enter the cell by passive diffusion and upon binding to AR, a conformational change occurs
allowing AR to hyperphosphorylate, dimerize, recruit coactivators, translocate to the nucleus and
bind to target DNA (11, 12).
The AR gene locus is on the X chromosome at Xq11-12, containing 8 exons and coding
for a 919 amino acid protein with a 110 kDa mass (13). To unravel the receptor itself, a
compilation of studies have elucidated four functional domains within the structures of SHRs
2

(14, 15). Clinical, biochemical, and cellular experiments have also highlighted the important role
of AR, such as in male sexual differentiation and development in response to physiological
processes. The amino terminal transactivation domain (NTD) is the site of the major regulatory
domain, activation function-1 (AF-1) (16). The DNA-binding domain (DBD) is the hallmark of
nuclear receptors due to the high conservation of this domain in nuclear receptors. The DBD is
located next to the NTD where the zinc fingers in this area bind to the hormone response element
(17). Moreover, the hinge region (H) is poorly conserved, provides structural flexibility, and may
be a key site of receptor posttranslational modifications (18). Finally, the carboxy-terminus, the
ligand-binding domain (LBD), which contains the activation factor 2 (AF-2), is the site of
hormone binding (19).
The NTD is 556 amino acids long and has an important role in AR transactivation;
although it can interact with the LBD, transactivation can occur independently (13, 20). Its
structure remains unknown, however, predictive modeling suggests this region is a globular,
disordered, low complexity state upstream of the AF-1 region (21). Although the structure is
undefined, mutagenesis studies performed in androgen independent cells demonstrated that the
WxxLF motif is necessary for AR transactivation (22). In addition, GFP deletion mutant
transfections in PC-3 LAPC-4 and COS-1 cells revealed a critical region for cytoplasmic
localization. Δ50-250AR exhibited higher nuclear localization compared to full length AR,
which suggests this region promotes cytoplasmic localization mediated by exportin 1. This was
determined using Leptomycin B, which possesses nuclear export inhibitory functions in humans,
and led to inhibition of Δ50-250AR cytoplasmic localization. Additionally, at a high dose of the
synthetic androgen R1881, these constructs could continue to translocate, thereby proposing a
putative mechanism for progression towards castration resistant prostate cancer (CRPC) (23).

3

Much efforts have been made to therapeutically target the LBD of AR, a more modern
approach is to utilize antagonists for the NTD and block its transcriptional activity. One
challenging aspect of prostate cancer is the cross-talk that occurs with other signaling molecules
such as interleukin-6 (IL-6). IL-6 can activate NTD transactivation and increase proliferation
through the MAPK and STAT3 signal transduction pathways in LNCaP cells (24). For these
reasons, small molecule inhibitors EPI-001 and analogs have been designed to target this region
and disrupt NTD transactivation by binding the AF-1 region. In vivo, EPI-001 has an antiproliferative profile where the tumors of mice decreased after treatment and apoptosis increased
(25, 26). The NTD seems to be a plausible method to target with reduced detrimental side
effects; however, this does not eliminate drug resistance concerns.
The DBD is located in the middle region of AR and is responsible for binding DNA
through its two zinc fingers forming an alpha helix core in a manner that AR can hetero or homodimerize and interact with the major groove on the DNA. Upon folding of the first zinc finger,
the alpha helix forms allowing it to interact with the major groove in the DNA termed the P-box,
and further interacts with transcriptional enhancers (17, 27). The second zinc finger interacts
with the D-box and is retained by hydrogen bonding (28). The flexibility of the DBD is based
upon its interaction with the FxxLF motif in the NTD and the LBD. Interestingly, the binding of
an antagonist or an agonist has a major influence on where the DBD will bind to and initiate the
transcription machinery (29).

The requirements for DNA binding are not exclusive to its

structure; they bind to proteins that facilitate this process such as the AP-1 heterodimer
constituents Fos and Jun (30).
Receptor recycling and shuttling between cellular compartments are critical for activity
and post-translational modifications have a role in these processes. The hinge region is
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responsible for carrying two synergy control motifs that have inhibitory functions. Within the
AR motifs, acceptor lysines at positions K386 and K520 serve as post-translational modification
sites by small ubiquitin-like modifier (SUMO) proteins. This region is responsible for
suppressing AR activity and if mutated at these key residues, AR activity increases in vivo. A
mutation in this region has been found, in AIS and prostate cancer patients, and it can increase
AR transcriptional activity (31). Whole-cell and cell-free studies have demonstrated that
SUMOylation provides a mechanistic role for AR suppression, gene expression, and regulation
of nuclear localization (32-34). Collectively, these studies provide insight into the mechanistic
regulation by SUMO proteins and how they possess inhibitory functions. However, a role for
receptor-associated cochaperones in this process is not well understood.
The flexibility of the hinge region in AR promotes signaling pathways to partake a
crucial role in AR translocation. This mobility was demonstrated by Tanner and colleagues,
where mutagenesis studies performed in the (629)RKLKK(633) motif disturbed various aspects
of receptor function (35). Moreover, amino acid substitutions performed in Serine 650 to an
Alanine led to a decrease in transcriptional activity (36). In a similar fashion, Chen and
colleagues mutated S650A and sought to determine in a more detailed manner the regulation of
AR and Protein Phosphatase 1 (PP1). Co-immunoprecipitation studies showed that AR can bind
to PP1α in LNCaP cells and has a time-dependent nuclear entry. The interaction was proven to
be functional as these two proteins augmented transcriptional activity based on reporter assays in
LNCaP cells. PP1 inhibitors promoted dephosphorylation and nuclear withholding, suggesting
the functional interaction could provide clues to future drug targets in the hinge region (37).
Albeit the detailed mechanism between PP1 and AR is not well understood, the hinge region is a
plausible target for combinatorial drugs where much of the chemotherapeutic drugs are designed.

5

The hinge region possesses a characteristic acetylation motif for modification at the εamino lysine residues, which allows proteins to bind and enhance or repress DNA transcription
(38, 39). AR acetylation mutant L630A in comparison to wild type was unable to stimulate
transactivation upon ligand binding (40). On the other hand, mimicking this site potentiated
transactivation in a PSA promoter even in the presence of minimal hormone levels. Interestingly,
this somatic mutation is present in PCA patients providing another mechanistic aspect of
progression.
The LBD’s 12 alpha helices posed by the androgen receptor is very selective, dynamic,
and complex (41). The AF-2 region located in the LBD is a crucial player in recruiting
coactivators, which are responsible for regulating the transcription of AR-regulated genes. The
AF-2 region has promising therapeutic potential due to its binding function 2 (BF2) surface, a
hydrophobic cleft that binds alpha-helical peptides. Based on x-ray screens, this surface could
potentially serve as a target for small molecules that can regulate AR activity (42). Another
binding partner of AR is β- catenin, a protein that augments activation of transcription by the
initiation of the coactivator p160. Moreover, upon ligand binding, nuclear translocation occurs
because the nuclear localization signal (NLS) is able to respond to the zinc fingers, an event
mediated by importin. The two zinc fingers located in the hinge region mediate DNA binding
(43). Mutations in the androgen receptor regulatory sites discussed above are the cause of
androgen insensitivity syndrome (AIS) and likely contribute to prostate cancer progression.
Apart from the many functional domains within the receptors that could serve as therapeutic
targets, the receptors undergo a dynamic chaperone-mediated folding process involving a variety
of chaperone and associated cochaperone proteins, all of which also represent potential
therapeutic targets.

6

1.2 Molecular Chaperone-Mediated Steroid Hormone Receptor Maturation
Molecular chaperones and cochaperones have a critical role in SHR assembly and
stability (44). Based on their ability to serve as transcription factors, SHRs execute and regulate a
diverse set of developmental and physiological events in eukaryotes (2, 45, 46). Moreover, the
dynamic and complex molecular chaperone machinery is paramount for the folding, assembly,
and prevention of aggregation of these receptors (47, 48). In addition, the chaperone complex
plays a key role in monitoring and altering hormonal potency (49).

1.2.1

Early Complex
The dynamic chaperoning of SHRs is illustrated in Figure 1.1.1. The primary key steps to

initiate the molecular chaperone machinery consist of Heat shock protein 40 (Hsp40) binding to
the nascent SHR polypeptide synthesized by the ribosome in the cytosol. The existing model for
the chaperone machinery is based on evidence from several model systems such as baker’s yeast
Saccharomyces cerevisiae and rabbit reticulocyte lysate. The typical pathway involves a series of
steps: early, intermediate, asymmetrical, and mature to achieve a high affinity state for hormone
binding in a sequential time-dependent manner. There are five main proteins required for
receptor maturation: Hsp40, Hsp70, Hsp90, HOP, and p23 (46, 50-52). Initially, Hsp40 binds to
the LBD of the receptor, Hsp40 binds to the ATPase domain of Hsp70 through an HPD motif
and transfers the client protein to Hsp70 by hydrolysis (53-55). In vitro experiments using
chicken PR and rabbit reticulocyte lysate demonstrated that when Hsp40 was not present in the
complex, PR was unable to bind hormone with high affinity. However, the Pratt laboratory
proposed that Hsp40 was not essential for GR based on their stoichiometric studies with the
yeast homologue YDJ1 (52, 56). The mechanistic aspect of how this regulation occurs is not
fully understood; nonetheless, Hsp40 primes the client protein for the following steps in the
7

chaperoning pathway. There is still a lack of knowledge regarding the role Hsp40 has in disease
and the mechanism by which it influences SHRs.

8

Figure 1.1.1 Steroid Hormone Receptor Chaperone Complex Assembly.

9

Figure 1.1.1 Steroid Hormone Receptor Chaperone Complex Assembly.
Early complex assembly is initiated upon Heat Shock protein 40 kDa (40) binding to the nascent
steroid hormone receptor polypeptide residing in the cytosol. Hsp40 recruits Hsp70 (70) where
the fate of the nascent polypeptide is determined to proceed with the intermediate complexes or
towards proteasomal degradation. Carboxyl Terminus of Hsp70 Interacting Protein (CHIP) is an
E3 Ubiquitin Ligase that along with Bcl-2 associated athanogene (BAG) proteins directs
misfolded receptors towards the ubiquitin and proteasomal degradation pathways. In the
intermediate complex, Small Glutamine Rich TRP-containing Protein alpha (SGTA) binds to
Hsp70. Hsp70 (70) recruits Hsp70 Interacting Protein (HIP) and Hsp70-90 Organizing Protein
(HOP) forming a bridge for Hsp90’s (90) binding into the complex. As the nascent polypeptide
travels through the asymmetrical complex the immunophilins (I) bind in a competitive fashion to
Hsp90 (90) allowing for a conformational change. Further, the mature complex forms as HIP,
HOP, SGTA, fall off and a 23 kDa cochaperone (p23) stabilizes the receptor. Once the receptor
is in the native state hormone is bound with high affinity. The receptor is then able to translocate
to the nucleus, dimerize and bind to hormone response elements (HRE) to initiate gene
transcription.

10

1.2.2

Intermediate Complex
The client protein enters the intermediate complex when Hsp40 introduces it to the

substrate binding domain of Hsp70 (57). Hsp70 binds a multitude of proteins through the EEVD
recognition sequence, which is a conserved region where interaction with most TPR-containing
cochaperones occurs. Heat shock protein interacting protein (HIP) is a cochaperone that
facilitates substrate transfer from Hsp40 to Hsp70 in an ATP-dependent manner (58).
Mutagenesis studies demonstrate that the TPR region of HIP is critical for binding Hsp70, which
is a determinant for the fate of the client protein.(59). Depending on the fold of the receptor,
Hsp70 can send the substrate to degradation pathways via the triage complex involving carboxyl
terminus of Hsp70-interacting protein (CHIP) and Bcl-2- associated athanogene (BAG) or
progress the substrate to the mature complex. Recent studies have suggested that these pathways
are critical. The family of BAG’s is fairly large and is composed of various isoforms, which
seem to have a role with the chaperones or SHRs. For instance, BAG1M can inhibit GR, MR,
and PR, and BAG 1L can inhibit the aforementioned receptors including AR. It is believed that it
functions through Hsp70’s ATPase activity (60, 61). Moreover, competition occurs for Hsp70’s
ATPase domain. BAG1 and HIP often compete for this domain and BAG1 has a preference of
destabilizing Hsp70 (50). Further, the main protein important for quality control, the carboxylterminus of Hsc70-interacting protein (CHIP) is an E3 Ubiquitin ligase, which has a critical role
in detecting misfolded proteins; thereby sending them to degradation pathways (62, 63).
Nonetheless, if the client protein is ready to move to the mature complex, Hsp70-Hsp90
organizing protein (HOP) introduces the client protein to Hsp90 via its TPR region at the
carboxy-terminus (64, 65). A more recently identified cochaperone, Small Glutamine Rich-TPR
Containing Protein Alpha (SGTA), is a TPR-containing protein that can bind both Hsp90 and
11

Hsp70 but has a higher affinity towards Hsp70. SGTA can be introduced within the intermediate
steps due to its high affinity for Hsp70 (66-68). In addition, SGTA can negatively regulate AR,
GR, and PR (67, 69). Although the dogmatic chaperone cycle seems to be straightforward, there
is much cross-talk between cochaperones through competition for binding the chaperone proteins
and other possible mechanisms. Cyclophilin 40 (Cyp40) is an immunophilin that plays a major
role in the mature complex, yet studies have also demonstrated that it can bind to Hsp70 and
modulate its role. However, Cyp40 does not bind to the Hsp70 ATPase domain (70). Further
studies are needed to understand if the other immunophilins act in this manner. The TPR domain
allows them to interact with Hsp70 and/or Hsp90, but domain organization is key to their
functional and physiological relevance.

1.2.3

CHIP Degradation Pathways
Protein quality control within the chaperoning pathway is crucial and CHIP serves as the

bridge for undesired substrates. CHIP has a TPR (3 TPR motifs) domain at the amino terminus, a
middle helical hairpin region, and a carboxy U-box. The structure posed by CHIP gives it
flexibility and adaptability for recruiting substrates via its TPR domain and sending that substrate
to degradation pathways via the U-box due to its E3 Ubiquitin ligase activity, which
polyubiquitinates substrates leading to their degradation in the 26S proteasome (71, 72). CHIP
competes with HOP for Hsp70 binding; this is a rate-limiting step for substrates because they
will either go towards re-folding or degradation processes (73). BAG1 is a cochaperone that
collaborates with CHIP for Hsp70 binding. BAG1 binds to the 26S proteasome and is able to
send Hsp70 substrates to this degradation pathway (74). CHIP and BAG1 provide the
maintenance for protein quality control and could serve as therapeutic targets for diseases
involving protein aggregation including the neurodegenerative diseases.
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1.2.4 Mature Complex
Hsp90 is a highly abundant chaperone that has been extensively studied. It plays major
cellular roles and has massive implications in diseases such as cancer (75, 76). In the mature
complex, Hsp90 receives client proteins from Hsp70 via HOP (77). Once Hsp90 binds to the
client protein, Hsp70 and its associated cochaperones dissociate. Upon p23 binding the protein
complex becomes stable and once the immunophilin protein binds the receptor assumes a high
affinity hormone binding competent state (78). Further, immunophilins such as FKBP51,
FKBP52, Protein Phosphatase 5 (PP5), and Cyp40 compete for binding to the conserved EEVD
motif in the carboxyl terminus of Hsp90 via their common TPR domain (79-81). FKBP52
competes with Cyp40 for Hsp90 binding via the TPR (81). Additionally, GCUNC-45 is an
interactor of PRA and PRB, which binds to Hsp90 ATPase domain and prevents activation of the
ATPase activity by Aha1. It is hypothesized that the immunophilin component can translocate
the receptor. More so, FKBP52 can displace GCUNC-45 from HOP (82). Ultimately, FKBP52
and p23 bind to Hsp90 and stabilize the complex (83). Protein quality control is always in place
and these dynamic steps allow for receptor recycling or activation. Upon hormone binding the
SHR translocates to the nucleus, dimerizes, and binds to the hormone response element where
gene transcription occurs accordingly (84). The question of whether the Hsp90 heterocomplex
dissociates upon hormone binding as suggested by the in vitro models is currently a matter of
debate as there are a number of evidences suggesting that the molecular chaperones are required
for receptor interaction with the nuclear pore, and may associate with the receptor on the DNA.
In addition, the immunophilin components of the complex may have a role in these processes.
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1.3 Immunophilins FKBP51 and FKBP52
The Immunophilins belong to a group of proteins that can bind to immunosuppressive
drugs (rapamycin, FK506, and cyclosporine A) through their functional peptidylprolyl cis-trans
isomerase (PPIase) enzymatic domain (85). Immunophilins can be further divided into two
categories based on the drug they bind. For instance, cyclophilins bind to cyclosporine A and
regulate various cellular processes, and FK506 Binding Proteins (FKBPs) can respond to FK506
and rapamycin, and participate in protein folding (86, 87). These multi-functional proteins are
present in plants, yeast, bacteria, fungi, and mammals, and possess immunomodulatory activity
where they can regulate T cell proliferation and act as molecular cochaperones to regulate AR,
GR, and PR.
The family of immunophilin proteins consists of an assortment of proteins with a size
range of 12- 52 kDa in weight whose architecture is composed of three regulatory domains: FK1
at the N- terminus, FK2 in the middle region, and a TPR at the C- terminus (80). Studies
performed by the Smith lab were the first to associate FK506 Binding Protein 51kDa (FKBP51)
and FK506 Binding Protein 52kDa (FKBP52) with PR complexes, and to detail their regulatory
role based on their structural composition (80, 87, 88). The most closely related immunophilins
are FKBP51 and FKBP52 due to their roles within the Hsp90 heterocomplex. It is well
established that the chaperone and cochaperone proteins work in an orchestrated manner to assist
proper folding and regulation of SHRs (89). Particular focus has been on FKBP52 as a potential
drug target given its ability to potentiate AR, GR, and PR activity (87, 90). On the other hand,
FKBP51 is approximately 60% identical to FKBP52, yet FKBP51 suppresses SHR activity (79,
91-93).
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Studies over the past three decades have focused largely on the FKBP12-like domain
(FK1) domain, which is the critical functional domain for the regulation of SHR activity.
FKBP51 FK1 is composed of a central alpha helix and surrounded by five antiparallel beta
strands. This region contains a binding pocket (PPIase pocket) that is highly hydrophobic
allowing drugs like FK506 and rapamycin to bind.
The FK1 has a proline-rich loop that overhangs a functional PPIase enzymatic pocket,
although PPIase activity is not critical for FKBP52 regulation of receptor activity. To narrow
down which region within the FK1 domain is the most critical for function, a library of random
FKBP51 mutants was generated by error-pone PCR and these mutants were screened in receptormediated reporter assays in yeast. Interestingly, only two residue changes (A116V and L119P)
within the FKBP51 proline-rich loop, which make the FKBP51 loop more like that of FKBP52,
convert FKBP51 from a negative to a positive regulator of receptor activity (49). These data
suggest that the proline-rich loop within the FK1 domain is critical for the regulation of receptor
activity and may serve as an interaction surface within the receptor-chaperone complex. An
analysis of FKBP sequence similarity across species suggests that FKBP51 and FKBP52
functionally diverged some time after the boney fishes.
A striking difference between FKBP51 and FKBP52 can be observed in the 7-9 residues
linking the FK1-FK2 domains, also known as the FK linker. The FKBP52 FK linker has a Casein
Kinase II (CKII) phosphorylation site, which is phosphorylated by CKII in cellular models (95).
CKII phosphorylation was demonstrated to prevent FKBP52 binding to Hsp90 (96, 97) and to
abrogate FKBP52 potentiation of receptor function (93). FKBP51 lacks the CKII
phosphorylation site. The importance of CKII phosphorylation in vivo and the contribution of
this difference to the distinct functions of FKBP51 and FKBP52 are currently unclear.
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In addition to the FK1 region, the TPR is also critical for function in that it is required for
FKBP52 binding to Hsp90’s carboxy terminus EEVD motif (95). Site-directed mutagenesis
studies further demonstrated that a single point mutation (FKBP51K352A and FKBP52K354A)
abolished FKBP protein binding to Hsp90. Interestingly, not only is the TPR region important to
bind Hsp90 but so are the upstream and downstream regions (98).
TPR-containing proteins have been extensively studied to understand the nucleocytoplasmic shuttling of SHRs. Although much insight has been provided, the exact mechanism
is currently unclear. For instance, it remains unknown if the chaperone heterocomplex plays a
role in the nuclear pore complex (58). Evidence suggests that dynein and FKBP52 work in
concert for GR translocation into the nucleus (99). Confocal microscopy experiments have
revealed that GR is unable to translocate to the nucleus when Hsp90 is inhibited by
geldanamycin (100). Some evidence also suggests that FKBP52 may translocate to the nucleus
with the SHR, and confocal microscopy studies demonstrated that FKBP52 co-localizes with
receptors and additional transcription factors on the DNA independent of its interaction with
Hsp90 (102). Thus, the dogmatic chaperoning cycle illustrated in Figure 1.1.1 is likely a drastic
oversimplification regarding the roles of TPR-containing proteins within the SHR signaling
pathways. In addition to the regulation of receptor activity within the Hsp90 complex, the FKBP
proteins also have additional roles within cells. FKBP52 destabilizes microtubules, whereas
FKBP51 promotes microtubule assembly, and the functional and physiological significance of
these activities are currently unknown (101). More recently, FKBP52 was shown to interact with
and regulate NF-kB. Taken together, the data has firmly established the FKBP proteins as
relevant factors in SHR signaling and as attractive drug target for the treatment of hormonedependent diseases. While the role of the FKBP proteins have been extensively studied, novel
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TPR-containing proteins continue to be identified that may also have functionally important roles
in SHR signaling.
1.4 Small Glutamine Rich Tetratricopeptide Repeat Containing Protein Alpha
Small Glutamine Rich Tetratricopeptide (TPR) Repeat Containing Protein Alpha (SGTA)
is a 35 kDa cochaperone that is involved in numerous cellular processes from viral particle
assembly to apoptosis, cell division, protein quality control, and steroid hormone receptor
regulation (103-105). A complete list of the known protein interactors can be seen in Table 1.

1.4.1 SGTA’s Involvement in Viral Pathways
Two groups independently identified SGTA as a protein interactor for a variety of viral
proteins in yeast two-hybrid screens. Cziepluch et al first identified SGTA interacting directly
with the NS1 of Parvovirus H-1 using an in vitro interaction assay. Fluorescence microscopy has
also shown SGTA accumulation with NS1 H-1 nuclear bodies owing to specific recruitment.
Since NS1 protein is vital for driving viral DNA replication, SGTA’s association suggests a
similar biological role (106). Furthermore, cellular fractionation studies reveal SGTA in the
cytoplasm and nucleus of rat fibroblasts, while Western blot has demonstrated that SGTA is
ubiquitously expressed in rat tissue (104, 107). SGTA is chromosomally located on 19p13 based
on in situ hybridization, and is ubiquitously expressed in human tissue as shown by Northern blot
(108). Given this, it appears that SGTA is associated with many maintenance pathways in a
predominantly inhibitory role.
Callahan et al used a yeast two-hybrid screen to detect unknown interactors with Viral
protein U (Vpu) and identified SGTA. They presented SGTA as U-binding protein (UBP) for its
in vitro and in vivo interaction with Vpu and Gag protein of HIV-1 (103). Vpu and Gag proteins
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have collaborative functions and are critical for viral entry and exit (109, 110). Interestingly,
GST-UBP (SGTA) was able to co-precipitate with Gag protein directly in vitro. However,
transiently transfected HeLa cell lysates were used for in vitro binding assays and in the presence
of Vpu, GST-UBP (SGTA) was unable to bind Gag protein. Additionally, a p24 ELISA
exhibited that UBP (SGTA) can negatively regulate HIV-1 particle release (103). The
aforementioned experimental data suggests that UBP (SGTA) can mediate the interactions
between these two proteins perhaps via its TPR. In an effort to further understand SGTA’s
regulation with Vpu and Gag, immunofluorescence studies demonstrated that SGTA associates
with actin filaments and microtubules. Upon treatment with the microtubule-destabilizing agent,
colchicine, SGTA remained associated with microtubules. However, when assessing SGTA’s
association with microtubules in a detergent-dependent manner, cellular fractions were unable to
associate (111). Collectively, these studies have demonstrated that SGTA can inhibit viral
particle release and is involved in distinct pathways from different viral families.
Severe acute respiratory syndrome coronavirus (SARS-CoV) 7a is another interacting
viral partner of SGTA mediated by its TPR region (112). In addition to the human interaction,
SARS-CoV7a co-immunoprecipitated with the African Green monkey SGTA from Vero E6
cells. Co-localization studies demonstrated that SGTA translocates to the nucleus with SARSCoV7a and that SGTA could be an accessory protein important for viral particle formation. The
presence of SGTA in the cytoplasm and nucleus are in line with the previously established
reports.
The Rec protein of Human endogenous retroviruses HERV-K (HML-2) adds to the list of
viral proteins interacting with SGTA by means of a yeast-two hybrid screen, and co-localize
through SGTA’s TPR domain (113). Since HERVs are endogenously expressed in human cells,
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they have been implicated in cancer progression due to their oncogenic properties (114, 115). In
prostate cancer cell lines, HERV-K transcripts and splice variants were present suggesting a role
for these endogenous retroviruses in PCA progression (116). In addition to binding and colocalizing, HERV-K (HML-2) masks SGTA’s ability to inhibit AR function. HERV-K (HML-2)
up-regulates AR by preventing SGTA binding to the chaperone complex of AR leading to
enhanced AR-mediated transcriptional activity. These interactions are functionally relevant
because they can play a major role in tumor progression and lead to the next generation of drug
targets.

1.4.2 SGTA’s Functional Role with Hsp70 and Hsp90
SGTA binds to molecular chaperones and possesses cochaperone activity as evidenced
by multiple biochemical studies. SGTA can bind to Hsp70’s C-terminus, which has a conserved
EEVD motif that is known for regulating chaperone activity mainly through its TPR domain
(117, 118). Similar to Hsp70, SGTA’s TPR domain is responsible for binding to Hsp90 (66).
SGTA's binding affinity for Hsp70 is 6.1µM, whereas its affinity for Hsp90 is 11.0µM. Although
SGTA has similar in vitro affinities to Hsp70 and Hsp90, it preferentially precipitates with
Hsp70 (67). Furthermore, SGTA forms a synaptic protein chaperone complex with Hsc70 and
Cysteine String Protein (CSP) where it has effects on misfolded proteins near the synaptic
vesicle surface (119). In addition, SGTA shows suppressive toxicity effects through its
interaction with intracellular β amyloid peptide (120). SGTβ, an isoform of SGTA was found to
be exclusively in the rat brain and can bind to Hsc70 and CSP. SGTA and SGTβ operate in a
similar fashion mainly by binding Hsc70 and CSP through their TPR domain, and it was
suggested that they work in conjunction to regulate the central nervous system, which might be
pertinent for neuronal protection (121). Moreover, based on co-immunoprecipitation
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experiments, the N-terminal region of myostatin interacts with the TPR and the C-terminus of
SGTA (122). Myostatin is mostly present in skeletal muscle and has a negative regulatory role
(123). The association of SGTA with myostatin contributes to the list of proteins towards which
SGTA has an inhibitory role.
Mounting evidence has suggested that SGTA plays a “housekeeping” role in cellular
processes. Primarily, Winnefeld and colleagues observed that SGTA is required for cell cycle
progression. A time-lapse microscopy video depicted that SGTAKDHeLa cells stayed longer in
mitosis and exhibited delays in prometa- or metaphase in comparison to wild type HeLa cells.
The complex formed by Hsp70, SGTA, and Bag-6 was able to co-precipitate in prometaphase
cell extracts (124). In addition, Wang et al extended the previous observations and demonstrated
that SGTA promotes apoptosis in 7721 cells and showed that the TPR motifs are critical for this
function (122). The three structural units were identified and individually tested for functionality
by Wang and colleagues. They concluded that the TPR interacts with Hsp90. Additionally,
because of the close association with Hsp90 in HeLa cells, SGTA displays pro-apoptotic
function (105). It can be reasonably concluded that the TPR region plays a pivotal role in cellular
interaction (125).
Although the work cited above provides convincing evidence that SGTA’s structural
domains are relevant factors that contribute to cellular roles and protein-protein interactions, the
precise functions are completely unknown in prostate cancer progression. For instance,
Buchanan and colleagues demonstrate that SGTA down-regulates AR. They suggested that this
effect retains AR in the cytoplasm and serves as a rheostat for its control. Moreover, in silico
docking analysis predicted that SGTA interacts with AR’s hinge region. However, definitive
proof of this proposed mechanism is lacking. On the other hand, Paul et al sought to determine if
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this novel regulatory role posed for SGTA works similarly for other nuclear receptors. A
sequence alignment showed that human SGTA and S. cerevisiae Sgt2 share approximately 30%
amino acid identity (Figure 2.3.3). Moreover, they have three regions required for function: Nterminus, TPR, which is the most conserved across species (108), and Q-rich region (67). SGTA
is a negative effector of GR and PR, however, there was no effect on MR and ER activity. To
further validate such interactions, HeLa SGTA KD cell lines were generated. In luciferase
reporter experiments, the absence of SGTA increases receptor function. On the contrary, when
SGTA is present the negative effect remains. Furthermore, a yeast two-hybrid analysis
demonstrates SGTA associates with GR and PR. This result does not demonstrate a direct
interaction with the receptor, but it does suggest an association with receptor-chaperone
complex. The data indicate that SGTA is a specific negative regulator of AR, GR, and PR
activity.
Based on SGTA’s involvement with PCA, many efforts have been made to understand if
SGTA is a contributor to PCA progression. The knockdown of SGTA in C4-2B cells had a
significant alteration in AR target genes, and potentiates Akt activity (126). C4-2B cells have
been derived from a LNCaP PCA cell line and exhibit castration resistant features (127).
PI3K/Akt signaling has been implicated in PCA progression and activation is observed in CRPC
(128). This line of evidence is in stark contrast to what Buchanan et al published since AR’s
activity was inhibited in PCA cells (69). Our lab has also observed that SGTA is a transcriptional
repressor of AR (67). Perhaps this indicates SGTA is a protein reliant on tissue and system
specificity for its regulation.
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1.4.3 SGTA’s Involvement in Protein Quality Control
The first report of SGTA in protein quality control pathways was performed by Schantl et
al. They determined that SGTA’s TPR region is critical for its interactions with the ubiquitindependent endocytosis (UbE) motif of the growth hormone receptor (129). Although it is not
involved in the ubiquitin pathway, it seems this interaction is critical for the fate of the growth
hormone receptor perhaps due to SGTA’s interactions with Hsp70 and CHIP in the intermediate
chaperone pathway. Moreover, the endoplasmic reticulum is the entry site for the transmembrane
domain recognition complex of 40 kDa (TRC40) and this complex is driven by chaperones
(130). Tail anchored (TA) proteins constitute a majority of biosynthetic pathways and function
in an ATP-dependent manner (131). Sec61β is a TA protein that interacts with SGTA and
facilitates membrane entry (132). The Bcl-2 associated athanogene-6 (BAG6) is a
multifunctional cochaperone that collaborates with Hsp70 to enhance protein quality control by
sending substrates to degradation pathways (133). Remarkably, SGTA plays a role in promoting
deubiquitination of mislocalized proteins from BAG6-mediated protein triage by masking the
hydrophobic regions (134-136). SGTA binds to Rpn13, which is a proteasomal ubiquitin
receptor, and can prevent proteasomal degradation (137). The yeast homologue of SGTA, Sgt2,
is involved in the TA protein pathways as well. The Guided Entry of TA proteins (GET)
pathway is composed of Get3, Get4, and Get5 proteins that form a complex and are ATP-driven
to direct newly synthesized proteins to their respective locations (138, 139). Sgt2 is involved in
this pathway by loading the TA protein onto Get5, by binding to the Ubl domain of Get5 (140,
141). Based on structural studies, the dimerization domain of SGTA and Get5-UBL interaction is
mainly driven by electrostatics (142). Thus far, these studies have demonstrated that SGTA
along with partners from the BAG6/UBL containing protein complexes recognize and propel
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proteins towards biosynthesis or degradation mechanisms. SGTA has become an increasingly
relevant factor in protein quality control and it would be interesting to determine if SGTA can
determine the fate of SHRs and thus, influence their negative regulation.
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Table 1: SGTA Protein Interactors
Protein
Interactor
NS1-Parvovirus
H-1

Method of
Discovery
Y2H

2

Vpu and HIV-1
Gag

Y2H

3

Hsp70

Y2H

4

Cysteine String
Protein

Y2H

5

UbE motif of
growth hormone
receptor

2D-gel, MS

6

N-terminal
myostatin

Y2H

7
8
9

Hsp90B
SARS-CoV7a
Bag6/Bat3/Scyt
he

2Hybrid
Co-IP-MS

AR

Y2H

11

Nuclear
proteome

2D-gel,
MaldiTOF

AR, pACT2-pooled
prostate cDNA
library
Embryonic Stem
cells

12

PDGFRalpha

phosphoprot
eomic study

PDGFR alpha, in
cancer cell lines-

1

10

Bait
H-1virus NS1,
FREJ4 cDNA
library
Vpu, Human Blymphocyte cDNA
library
Hsc70, human liver
cDNA library
rat CSP1 and rat
brain library as prey

GHR and truncated
GHR, HepG2 cells

SGTA-FLAG, HeLa
cells
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SGTA Relevant
Regulatory Role
Can be modified by
parvovirus infection.
Plays a role in virus
assembly or release
and inhibits viral
particle release.
TPR associates with
Hsp70.
Forms a complex with
Hsp70 and together as
a complex work to
inhibit
neurotransmitter
release.
SGTA first TPR
specifically interacts
with the UbE but does
not have a role with
ubiquitin system.
SGTA's third TPR
motif was crucial for
interaction with N-ter
of myostatin, may
play a role in
myostatin secretion
and activation.

SGTA might be
involved in mitosis, as
a complex, bag-6/bag3/scythe could be
required for complete
chromosome
progression.
SGTA negatively
regulates AR.
Part of the nuclear
proteome along with
SUMO.
S305 SGTA critical
for PDGFRalpha
stabilization and cell

Year

Citation

1998

(104)

1998

(103)

1999

(117)

2001

(121)

2003

(129)

2003

(122)

2006
2006
2006

(105)
(112)
(124)

2007

(69)

2010

(143)

2010

(144)

survival.
13

TRC40
Substrate:
Sec61βOPG

Purified recombinant pull down

14

HERV-K(HML2) Rec

Co-IP in
HEK293T
cells

15

SV40

Purified recombinant pull down

16

GR and PR

Y2H

17

Rpn13

Y2H

Purified
recombinant pulldowns with Rpn13

18

REIC/DKK-3

Y2H

REIC/DKK-3,
normal human heart
and prostate cDNA
library
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SGTA helps with
accommodating
substrates with
PEGylated TA region,
and helps integration.
Rec protein disrupts
SGTA's negative role
in AR and leads to a
vicious cycle
increasing cell
proliferation and
inhibition of apoptosis
eventually leading to
tumorigenesis.
Completes ER
membrane penetration
in a nonenveloped
virus.
Down-regulates GR
and PR.
SGTA is involved in
protein quality control
with BAG6 complex
and operates in 19S
regulatory particle.
Helps to escape
proteasomal
degradation and
selectively modulates
substrate degradation.
Binding to
REIC/DKK-3 this
interferes with SGTA
dimerization,
promotes dyneindependent AR
transport then
upregulates AR
signaling.

2011

(132)

2013

(113)

2014

(145)

2014

(67)

2015

(137)

2016

(146)

1.5 SGTA, FKBP51, and FKBP52’s Role in Disease
TPR-containing proteins have the potential to impact a diverse set of hormone-dependent
physiological processes and diseases. In terms of understanding these diseases at the molecular
level, molecular chaperones and cochaperones have been extensively studied since they are
involved in the SHR regulation. Acquiring knowledge on how these proteins associate with and
regulate the receptors will provide novel targets and strategies for the treatment of diseases.
The first studies to relate FKBP52 in a physiological context were performed by CheungFlynn and colleagues where a FKBP52 knockout (52KO) mouse model was generated. They
characterized the critical importance of FKBP52 in the male and female reproductive tract. An
apparent difference in the FKBP52KO model compared to the wild type was the presence of
nipples and internally, the seminal vesicles and anterior prostate were mainly absent creating a
link to Androgen Insensitivity Syndrome (AIS). AIS is characterized by the lack of androgens
present in males where symptoms such as ambiguous external genitalia, a dysgenic prostate, and
nipples are notable. Interestingly, mice lacking FKBP51 and FKBP52 were embryonically lethal
suggesting redundant roles for these two proteins in embryonic development (147).
It has been established that FKBP52 is critical for normal male and female reproductive
development and success. Congenital anomalies such as hypospadias have been affiliated with
FKBP52, and an increase in infant birth defects has been reported (148). Anatomical defects
have been affiliated with FKBP52 based on the previous FKBP52KO mouse studies. In addition,
in human samples, immunohistochemistry studies from the epidermis of the penile skin
demonstrated the presence of FKBP52. Nonetheless, genetically, there were no FKBP52
mutations in these samples (149). In addition, it has been reported that FKBP52 plays a relevant
role along with AR for urethra morphogenesis. In situ hybridization showed that there were
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higher levels of FKBP52 present in the ventral rather than the dorsal aspect of the male penis
(150).
In female mice, FKBP52 is critical for implantation given that embryos failed to implant
after fertilization in 52KO mice. This phenotype is consistent with FKBP52's positive role in PR
signaling based on cellular and biochemical evidence (151). Studies have established that
FKBP52 also plays a role in Endometriosis. Immunohistochemistry studies performed by the
Dey group showed that 52KO female mice, as compared to the wild type, had endometriotic
lesions. They sought to determine if angiogenesis played a collaborative role with FKBP52. In
the 52KO mice there was increased inflammation and angiogenesis. The extent as to which
FKBP52

influences

angiogenesis

is

not

well

understood.

In

a

clinical

setting,

immunohistochemistry revealed that FKBP52 expression was low in human endometriosis
samples (152). More recently, a more detailed role for FKBP52 in reproduction has been
established; depending on the stage of pregnancy FKBP52 forms a complex with hormonebound PR (153, 154).
A role for FKBP52 is not exclusive to sexual development, but it also appears to be a
critical component of other diseases such as prostate cancer. In human prostate cancer tissues,
up-regulated expression of FKBP52 is observed (155). Thus far, the emphasis for targeting
prostate cancer has relied heavily on Hsp90, but a novel approach is to target immunophilins
based on their molecular and physiological importance. With this in mind, De Leon and
colleagues screened a small molecule library from which the lead compound MJC13 shows a
decrease in cancer cell proliferation. The lead compound was capable of “freezing” the mature
Hsp90-FKBP52-AR complex and retaining the complex in the cytoplasm (156). The data
demonstrate that targeting the regulation of AR by the FKBP52 cochaperone is an effective
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strategy that could by-pass mechanisms of disease resistance observed with the current
antiandrogen therapies currently used in the clinic.
The neuroendocrine effects that involve FKBP52 are minor as compared to the closely
related FKBP51 protein, which results from FKBP51's negative regulation of GR in a tissuespecific manner. However, FKBP52 can regulate GR as well and behavioral studies have shown
that 52KO mice demonstrate an anxiety-related behavior. In addition, 52KO mice had higher
levels of stress as compared to wild type suggesting that FKBP52 has a specific role with GR in
the HPA axis. This regulatory role remains unknown and it would be interesting to understand
the difference that FKBP52 and FKBP51 have on GR specificity in neuroendocrine disorders
(157). Moreover, based on the interaction FKBP52 has with tau proteins this interaction is likely
to be critical for Alzheimer’s Disease (AD). Indeed, in AD, FKBP52 is present in extremely low
levels in the frontal cortex of patients with AD as compared to controls (158). Although the role
of tauopathies is well studied, the role of FKBP52 remains elusive. A metabolic role for FKBP52
with GR has also been established. A study mimicked the metabolic syndrome in mice lacking
FKBP52, as well as in wild type mice. 52KO mice became GR-resistant leading the liver to
retain fat (159). Mounting evidence based on animal and cellular studies demonstrate that
FKBP52 has a meaningful role in physiological processes. Thus, using FKKBP52 as a molecular
target for numerous diseases can be extremely useful and, yet understanding the exact
mechanism as to how FKBP52 can regulate receptor is needed.
FKBP52, a positive regulator, shares the same specificity as SGTA for receptor
regulation. A receptor-mediated reporter assay in yeast demonstrated that SGTA abrogates
FKBP52-regulated receptor function. Further, a human tissue blot, based on their physiological
relevance to AR, GR, and PR, was used to assess tissue-specific expression patterns of FKBP52
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and SGTA and a similar pattern of expression in the tissues was observed. Higher expression is
present in the testis, brain, ovaries, and liver, and its expression is lowest in the ovary. Moreover,
SGTA and FKBP52 both possess TPR regions and this effect could be due to a competition for
binding the EEVD motif on Hsp90. Collectively, these data suggest that there is a physiological
relevance and that SGTA can have multiple functions in the cell. The immunophilin FKBP51
that is highly similar to FKBP52 does not have a dramatic effect on receptor function like SGTA
(67).
SGTA has been implicated in various diseases such as Polycystic Ovary Syndrome
(PCOS), and based on its regulation with the AR-chaperone complex, it may contribute to the
pathogenesis of PCOS (160-162). Unfortunately, gynecological carcinomas are a major threat for
woman in the United States as the SGTA/AR ratio is altered and this alteration influences
subcellular localization (163). The SGTA/AR ratio seems to be low in reproductive cancers
contributing to progression. Immunohistochemistry studies demonstrated that SGTA is expressed
in Non-Hodgkin’s Lymphomas (164), esophageal squamous cell carcinoma (165), human
hepatocellular carcinoma (166) and, non-small-cell lung cancer (167). Collectively, these studies
made SGTA a contributor of tumor cell proliferation, differentiation, and poor prognosis.
1.6 Prostate Cancer Mechanism of Action: Classical and Contemporary Approaches
Prostate cancer is a moral and economic burden to families in the United States. In 2015,
PCA accounted for 220,800 newly diagnosed cases and approximately 27,540 deaths according
to the American Cancer Society. African American males are at higher risk than other races,
making this a health disparity that requires immediate research attention. Prostate cancer is
typically terminal once it becomes castration-resistant. For early stage cancers, current effective
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treatments include antiandrogens, which antagonize the androgen receptor. However, as PCA
progresses to castration resistance these treatment options become ineffective. AR is a promising
target for PCA, yet the mechanisms of androgen-independence remain unclear (168).
There is substantial evidence showing an important role for the Hsp90 chaperone
machinery in ‘client’ protein (e.g. AR) folding and function. Hence, Hsp90 also serves as a
therapeutic target for PCA. Hsp90 inhibitors have been in clinical trails since 1999 where only
three molecules have been introduced in the clinic. Trepel et al suggest that cancer cells are
addicted to chaperones like Hsp90 due to a cancerous (stressed) state (169). Development of
strategies like androgen antagonism, blocking androgen synthesis, and Hsp90 inhibitors to
degrade AR are revolutionizing the fields as well (170). Moreover, mutations in AR are present
in primary tissue samples and cell lines where the exploitation of this fact has served to
investigate novel mechanisms and alternate sites for PCA. AR structural regions are also under
investigation where it is believed that by blocking functionally relevant coactivators of AR better
therapeutic approaches can be achieved (43, 171, 172).
Other strategies to target PCA are through the roles AR splice variants (AR-V7) have on
CRPC. The most recent findings in this area show that AR splice variants remain resistant to
inhibitors as compared to full length AR and are constitutively active (11). The difference
between full-length and AR-V7 is that the ligand domain which is located at the C- terminus in
AR is lacking (173). This means that even though its specificity for and activation by a ligand is
lacking, AR-V7 can homodimerize or heterodimerize with the full-length AR and thus initiate
transcription of target genes (174). The splice variant mechanism is suspected to contribute to
the escape of the normal AR mechanism due to its truncated domain (175). This constitutive AR
signaling bypasses the classical therapies.
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Novel therapies involving the androgen synthesis pathway, AR signaling inhibition, and
degradation of AR seem to be the most effective strategy for targeting the splice variants (176).
Unfortunately PCA signaling will find means to bypass the novel therapies. In PCA sample
tissues, an overexpression and up-regulation of AR-V7 is observed mainly in the CRPC stage
(177). The exact mechanism as to how these contribute to progression and can remain
constitutively active remains unknown. One interesting hypothesis is that AR-V7 is developed as
a compensatory mechanism when a patient undergoes Androgen Deprivation Therapy (ADT)
(178).
In addition to AR, GR has been speculated to be a driving force for CRPC. GR belongs to
the nuclear receptor superfamily and can activate an analogous transcriptional sequence (179).
An interesting study was performed by Xie and colleagues in which they demonstrate, through a
PCA tissue microarray, an upregulation of GR genes in CPRC. However, these genes were not
altered in a pre-castration model suggesting that GR is repressed by AR (180). In a similar
manner, PR has the capacity to activate CRPC and nuclear PR was present in PCA sample
suggesting that it may be associated with the transition from a pre-CRPC to CRPC (181). The
SHRs share structural domains and have the capacity to activate similar pathways in a unique
manner. An exciting approach is being developed in Dr. Cox’s laboratory in which the targeting
of the FKBP52 cochaperone directly would inhibit a variety of protein known or thought to have
a role in PCA progression including AR, GR, and PR.
1.7 Current Research Focus
In the present study, I demonstrate the binding affinities of SGTA for Hsp70/90. A PR
reconstitution assay demonstrates that SGTA does not affect chaperone complex formation and
is not vital for receptor hormone binding. In studies comparing full-length versus a ΔQ-rich
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SGTA mutant at the C- terminus, the ΔQ-rich mutant fails to abrogate AR activity in a yeast
receptor-mediated reporter assay. This demonstrates the importance of the Q-rich region at the
C-terminus of SGTA for AR signaling, and that SGTA regulation of SHRs is not based solely on
its ability to interact with Hsp70/90. Additionally, SGTA antagonizes Peroxiredoxin 1
potentiation of AR activity in HeLa-SGTAKO and 22RV1-SGTAKO cell lines. SGTA and
PRDX1 can interact directly in vitro in the absence of other proteins, as demonstrated by a
FLAG-pull down assay using purified recombinant proteins. Thus, SGTA remains a relevant
factor due to its ability to associate with and antagonize positive-regulators of AR.
1.8 Hypothesis
Molecular chaperones are responsible for regulating the folding and activation of steroid
hormone receptors (SHRs). The dynamic exchange of factors, and the type of protein-protein
interactions involved is critical for SHR regulation in physiological processes. However, the
precise molecular mechanism that drives these SHRs to function remains poorly understood.
This knowledge is necessary because in late stage prostate cancer the androgen receptor can be
activated upon exposure to molecules other than ligand. Because of this, the receptor can be
continually activated as seen in castration resistant prostate cancer. The cochaperone SGTA is
crucial in the down-regulation of androgen, progesterone, and glucocorticoid receptors.
Moreover, our results have also indicated that when SGTA is co-expressed with the
immunophilin FKBP52, SGTA can partially abrogate receptor function. However, receptor
reconstitution assays in vitro demonstrate that SGTA is an independent regulator in receptor
function because hormone-binding levels were not affected. We hypothesize that SGTA is acting
as a non-competitive inhibitor of FKBP52 function by binding to intermediate receptor
chaperone complexes preventing the receptor from reaching the native folded state on which
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FKBP52 acts. In prostate cancer, SGTA levels are down-regulated and FKBP52 levels are upregulated, thus implying that SGTA may play a key role in governing negative feedback (Figure
1.1.2).
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Figure 1.1.2 SGTA Regulatory Hypothesis in Normal versus Prostate Cancer Activity
In a normal prostate, SGTA inhibits AR regulation while FKBP52 promotes it to maintain
homeostasis in a normal prostate setting. In Prostate Cancer, AR hyperactivity is observed in
which SGTA expression levels are decreased and FKBP52 expression levels are up-regulated
which drives AR to a hyperactive state and disrupt this homeostatic balance.
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1.9 Dissertation Goals
The overall target of this work is to understand the structural and functional role SGTA
plays in androgen receptor signaling. Based on our knowledge that SGTA can abrogate androgen
receptor function, and that it is down-regulated in prostate cancer, it is relevant to understand the
important SGTA functional domains and/or residues. In addition, the identification of SGTA
interactors that could abrogate the negative regulation of AR by SGTA could lead to novel drug
targets for the treatment of PCA. An effort has been made to understand SGTA’s regulation
towards the androgen receptor by addressing the following questions:

1. Which domain is important for SGTA’s functional role?

2. Does SGTA belong to the intermediate/mature complex in the chaperone machinery?

3. What are the global SGTA interacting proteins in prostate cancer cells and do any of
these interactions antagonize SGTA regulation of AR?

In addressing these questions, we will contribute to the knowledge by which a specific domain is
regulating AR and its role in the chaperone machinery towards receptor folding and regulation.
Additionally, we will provide evidence of previously unknown SGTA interacting partners and of
their putative functional role. In testing our hypothesis, we will have an understanding of
SGTA’s role in prostate cancer progression.
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Chapter 2: Functional Characterization of SGTA Interactions with the
Androgen Receptor
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2.1 Rationale
Initial studies demonstrated that SGTA is a novel cochaperone that interacts with Hsp70
and Hsp90, and down-regulates AR by binding to its hinge region (68, 69, 105, 118). More
recently, our laboratory demonstrated that SGTA associates with and negatively regulates GR
and PR complexes as well (67). SGTA is comprised of a unique N- terminal dimerization
domain, a middle TPR domain, and a glutamine-rich C-terminus (66, 125). Currently, SGTA is
known to interact with Hsp70 and Hsp90 through the conserved C-terminal EEVD motif (66, 68,
118). Nevertheless, it is unknown whether the binding affinity towards Hsp70/90 interaction is
essential for the steroid hormone receptor maturation process, or whether the regulatory domains
are capable of having a functional effect. Here we sought to determine the binding affinities of
SGTA and Hsp70/90 to better understand if these affinities play a role in the receptor maturation
process.
Another TPR-containing protein, FKBP52, is similar in that the TPR mediates
interactions with Hsp70 and Hsp90 to regulate AR activity (49, 93, 182). Based on these
similarities, we sought to determine whether SGTA had the ability to influence FKBP52
regulation of AR (67). Our previous studies in a yeast reporter assay in which we co-transformed
FKBP52 and SGTA showed SGTA had an antagonistic effect on FKBP52’s ability to regulate
AR and GR. Initially, we hypothesized that SGTA and FKBP52 were competing for
Hsp70/Hsp90 MEEVD binding motif through their TPR domains. To further understand this we
utilized a well-established in vitro progesterone receptor reconstitution assay to investigate
whether SGTA associates with intermediate complexes, thus preventing the receptor from
reaching the mature complex (183).
In addition to SGTA’s role in the chaperoning pathway, we assessed which SGTA
domain(s) were critical for regulation of AR activity. The extent to which the down-regulatory
effect on nuclear receptor activity is dependent on SGTA’s structural domains has not been
established. Therefore, we generated truncation mutants and tested them in a well-established
functional yeast reporter assay system (184, 185).
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2.2 Materials and Methods
2.2.1 CONSTRUCTS
Construction of Truncation Mutants: Dutta et al. were the first to determine the structure of
SGTA (125). However, the extent of each domain's function remains elusive. Therefore, to
assess the significance of the three distinct domains, truncation mutants were generated. A
translation stop codon was introduced at the desired location to produce each truncation mutant.
To obtain these constructs, we used the QuickChange kit (Stratagene) and standard procedures.
The full-length SGTA yeast expression vectors served as the template. Upon completion of the
yeast truncation mutants, the plasmids were transformed into the yeast strains. A hormoneinducible β-galactosidase reporter plasmid, a LEU2-marked high copy number plasmid
constitutively expressing the androgen receptor from a glyceraldehyde phosphate dehydrogenase
(GPD) promoter, and a HIS3-marked high copy number plasmid with the truncation mutant, thus
allowing for growth and assessment of function. Transformants were selected with medium
containing synthetic complete dextrose lacking leucine, uracil, and histidine. Confirmation of the
construct was performed by DNA sequencing at UTEP’s BBRC DNA Analysis Core Facility.
2.2.2 Receptor-Mediated Reporter Assays in Yeast
Yeast reporter assays are used to record steroid hormone receptor activity by means of
measuring β-galactosidase. Standard procedures were followed as with Balsiger et al. and
modified as necessary (184). Three independent isolates were grown overnight in 5 ml of
selective medium lacking leucine, uracil, and histidine in a shaking incubator at 30°C. To ensure
that the yeast exhibit logarithmic growth, overnight cultures were diluted to an OD600 of 0.08,
and growth was monitored by spectrophotometry approximately 20 minutes after dilution. Next,
dihydrotestosterone (DHT) was added and incubated in the shaking incubator at 30°C for two
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hours. To measure β-galactosidase activity, in a 96-well plate, 100 µl of culture and 100 µl of
Gal-Screen TM substrate (Appplied Biosystems) were mixed, covered to avoid evaporation, and
incubated for two hours at room temperature. Post two-hour incubation, the plate was read in a
luminometer (BioTek). Relative light units were normalized to the optical density of the cultures
and plotted as a percentage of the activity in the presence of the empty vector alone (lacking
SGTA expression). The normalized data were plotted in GraphPad Prism Software. The data
reported is performed in triplicate clonal isolates and in at least three separate experiments. The
empty yeast expression vector (p423-GPD) served as our control, and full-length SGTA was
used to compare the functional differences of the truncation and chimeric proteins.
2.2.3 Western Blot Analysis
Overnight yeast cell culture was pelleted upon exponential phase growth. The pelleted
yeast cells were washed using HyPure Grade Molecular Water (Thermo) then resuspended in
yeast cell lysis buffer (20mM Tris-HCl, pH 7.4, 50 mM NaCl, 5% Glycerol) containing EDTAfree protease inhibitor cocktail (Thermo). To disrupt the yeast cell walls, glass disruption beads
0.5 mm for yeast/fungi (Research Products International Corp.) were used and vortexed
rigorously with the yeast cells containing lysis buffer plus protease inhibitor 7 times for 1 minute
each while placing the lysates on ice in between disruptions. The cells were then centrifuged for
20 minutes at 4°C at maximum speed to remove cell debris. The supernatant was saved and used
to perform a Bradford Assay using Coomassie Plus (Bradford) Assay Kit (ThermoScientific,
Pierce) according to manufacturer’s instructions. 30 µg of total cell lysate was loaded in a 1020% Criterion Gel (BioRad), and transferred to a PVDF membrane. The presence of SGTA was
detected using anti-SGTA antibody (ProteinTech), Androgen Receptor (Santa Cruz
Biotechnology; mouse monoclonal), and our loading control: L3, a mouse monoclonal antibody
(186). L3 is a ribosomal protein encoded by the TCMI gene and is the largest ribosomal protein
in S. Cerevisiae. All the above antibodies were alkaline phosphatase conjugated for use with the
Immun-Star AP Substrate (BioRad) upon exposure to X-Ray Film (Phoenix Research Products).
39

2.2.4 Statistical Analysis of Yeast Assay Data
Statistical analysis was performed using GraphPad Prism software. The data was
normalized to the vector and the mean assessed by one way analysis of variance followed by a
Bonferroni post-test and a value of p< 0.05 determined statistically significant values.
2.2.5 Recombinant Protein Expression and Purification
Purified recombinant human Hsp90∝ and Hsp70 were previously purified in the Buchner
lab (Department Chemie, Technische Universität München, Garching, Germany). SGTA was
cloned into pET28a(+) vector with a C-terminal His6 tag and into pGEX-4T-1 (a kind gift from
Dahai Zhu, Chinese Academy of Medical Sciences) with an N-terminal GST tag. The His6tagged and GST-tagged SGTA were both shown to be functional in the yeast reporter assays
(data not shown). For purification, the His6-tagged SGTA was expressed in Escherichia coli
BL21 (DE3). 30 ml of each overnight culture were grown in 1 liter of medium in a shaking
incubator at 37°C until the A600 reached 0.6. Protein expression was induced with isopropyl β–D1-thiogalactosidase to a final concentration of 1mM. The cultures were grown for an additional
4h and centrifuged at 6,000 rpm for 20 min. The pellets were resuspended in 12 ml of lysis
buffer (20 mM Tris-HCl, 300 mM NaCl, 10 mM imidazole, pH 8) and divided into three 4-ml
aliquots. 40 µl of 100 mg/ml lysozyme was then added to each 4-ml cell suspension and
incubated for 20 min at 30°C. To lyse the cells, each of the four samples were then sonicated and
kept on ice. The four aliquots were pooled together and centrifuged at 15,000 rpm for 20 min at
4°C. To purify the protein, the 12-ml lysate was loaded onto the nickel-nitrilotriacetic acid
column pre-equilibrated with lysis buffer and mixed for 1h at 4°C. The resin was then washed
with buffer (20mM Tris-HCl, 300 mM NaCl, 250 mM imidazole, pH 8) was used to elute the
proteins. All proteins were dialyzed extensively against 50 mM HEPES, 50 mM KCl, 10 mM
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MgCl2, 1 mM DTT (pH 7.4) prior to sample concentration and storage at -80°C. GST-tagged
SGTA was purified in a similar manner, except a glutathione resin was used and the buffer
formulations were as follows: lysis and wash buffer (50 mM Tris-HCl, 150 mM NaCl, 0.05%
Nonidet P-40, pH 7.5), elution buffer (10 mM reduced glutathione, 50 mM Tris-HCl, 1 mM
EDTA, pH 7.4).
2.2.6 PR-Chaperone Complex Reconstitution and Hormone Binding Assays
Purified PR was adsorbed onto PR22-protein A-Sepharose resin beads and reconstituted
into multiprotein complexes as described previously (183). Briefly, ~0.05 µM of PR was
incubated with 1 µM each of Hsp90β, Hsp70, Hop, Hsp40, p23, and indicated concentrations of
His6-tagged SGTA in 200 µL of reaction buffer A (20mM Tris-HCl, pH 7.5, 5 mM MgCl2, 2mM
DTT, 0.01% Nonidet P-40, 50 mM KCl, and 5 mM ATP) for 30 min at 30°C, resuspending
beads every 3-4 min. 0.1µM [3H] progesterone (American Radiolabeled Chemicals, Inc.) was
then added, and the reaction mixture was incubated for 3 h at 4°C on a gentle shaker. PR
multiprotein complexes were washed with 1 ml of reaction buffer B (20 mM Tris-HCl, pH 7.5),
0.01% Nonident P-40, 50 mM KCl) three times and assessed for bound progesterone using
Microbeta plate reader (PerkinElmer Life Sciences). The remaining samples were incubated with
SDS sample buffer, and protein complexes were resolved using SDS-PAGE (10% gel) and
Coomassie Blue staining. One-fifth fraction of each sample was run on SDS- PAGE (10% gel)
and transferred to PVDF membrane.
2.2.7 Isothermal Titration Calorimetry
Isothermal titration calorimetry was performed using a MicroCal VP-ITC instrument
(Microcal Inc., Northampton, MA). For the binding of human SGTA to Hsp90 or Hsp70,
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recombinant human GST-SGTA was titrated from the syringe into the cell containing human
Hsp90 or human Hsp70. The concentration of SGTA was 270 µM and the Hsp90 or Hsp70
concentration was 40 µM. In the case of Hsp90, the nucleotide dependence of SGTA binding
was tested by measuring the binding under the same conditions but in the presence of 2mM
AMP-PNP (Roche) in the cell. The buffer used in the syringe and the cell was 40 mM HEPES
(pH 7.5), 20 mM KCl, 5 mM MgCl2 at 25°C. 40 injections of ligand solution were performed to
fully saturate the protein in the cell. Data analysis was performed using Origin software
(OriginLab Corporation, Northampton, MA)
2.2.8 Isolation of His-Cpr6 and Ura2-TAP Complexes
Plasmids expressing wild type Sgt2 or Cpr6 containing an N-terminal His6 tag and
Xpress epitope expressed under the strong constitutive GPD promoter were transformed into an
hsc82hsp82 strain expressing untagged WT hsc82 or Hsc82ΔMEEVD. His-Sgt2 or His-Cpr6
complexes were isolated as described (187). Briefly, cells were grown overnight and harvested at
an A600 of 1.2-2.0. Cell pellets were resuspended in lysis buffer (20 mM Tris, pH 7.5, 100 mM
KCl, 5 mM MgCl2, 5 mM imidazole containing a protease inhibitor tablet (Roche Applied
Science)) and were disrupted in the presence of glass beads with eight 30-s pulses. Cell lysates
were incubated with nickel resin (1 h with rocking at 4°C) followed by washes with lysis buffer
plus 35 mM imidazole and 0.1% Tween 20. Proteins were eluted from nickel resin by boiling in
SDS-PAGE sample buffer, and protein complexes were separated by gel electrophoresis (10%
acrylamide) followed by Coomassie Blue staining. Alternatively, proteins were transferred to
nitrocellulose, and chemiluminescence immunoblots were performed according to the
manufacturer’s suggestions (Pierce). Anti-Xpress antibody was obtained from Invitrogen. AntiHsp70 (Ssa isoform) was a gift from Dr. Elizabeth Craig.
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2.3 Results
2.3.1

SGTA and Sgt2 interaction with Hsp70 and Hsp90
Previous studies demonstrated that SGTA interacts with Hsp70 and weakly with Hsp90

in coimmunoprecipitation experiments, and these interactions were mapped to the three tandem
TPRs between residues 95 and 195 on SGTA (68). To get a more quantitative measure of SGTA
binding to Hsp70 and Hsp90, we performed isothermal titration calorimetry with recombinant
human SGTA, Hsp70, and Hsp90 (Figure 2.3.1) These results indicate that SGTA binds Hsp70
with an affinity of 6.1 µM (Figure 2.3.1A) and to Hsp90 with an affinity of 11.0 µM (Figure
2.3.1B) in vitro. Despite the similar affinities in vitro, previously published data suggested that
SGTA precipitates predominately with Hsp70 in co-immunoprecipitations from mammalian cell
lysates (68). To further corroborate these findings, we isolated His-Sgt2 complexes to determine
whether Sgt2 interacts predominantly with Hsp70 or Hsp90 in yeast extracts. For comparison,
we also isolated His-Cpr6, which is known to interact with both Hsp70 and Hsp90, but not
Hsp90ΔMEEVD because of the deletion of the TPR binding site (187). As shown in Figure
2.3.1C, similar levels of Hsp70 bound His-Sgt2 and His-Cpr6. There was no noticeable effect of
the Hsp90ΔMEEVD mutation, suggesting that little or no Sgt2 directly binds Hsp90 in yeast
extracts.
2.3.2

SGTA Acts Independently of Receptor Maturation and Hormone Binding
Our data support the idea that SGTA acts at an early stage in receptor folding. Based on

this idea, we sought to determine whether SGTA influences receptor-chaperone complex
assembly and the folding of the receptor to a hormone-binding competent conformation. Thus,
we assessed the ability of increasing concentrations of recombinant SGTA to affect the assembly
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of PR-chaperone complexes in a progesterone receptor reconstitution assay using the five
purified proteins (Hsp90, Hsp70, Hop, Hsp40, and p23) known to be required for PR to reach a
hormone-binding competent conformation in vitro (Figure 2.3.2A). Although SGTA was able to
associate with PR-chaperone complexes, SGTA supplemented into the assay up to 16 µM had no
effect on PR-chaperone complex assembly. It is possible that additional endogenous factors are
required for SGTA function. Thus, in addition to the “five purified protein system,” we also
performed these assays in rabbit reticulocyte lysate (Figure 2.3.2B). SGTA did not affect PRchaperone complex assembly in both systems. In addition, SGTA had no effect on PR folding to
the hormone-binding competent conformation in reticulocyte lysate (Figure 2.3.2B, left panel)
and in the five purified protein system (data not shown). Thus, although SGTA can associate
with receptor chaperone complexes and functionally affect receptor activity, these effects are not
due to the alteration of receptor folding and hormone binding.
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Figure 2.3.1 SGTA and Sgt2 interaction with Hsp70 and Hsp90.
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Figure 2.3.1: SGTA and Sgt2 interaction with Hsp70 and Hsp90.
A and B, isothermal titration calorimetry was performed with recombinant SGTA (270 µM) and
either human Hsp70 (A) or human Hsp90 (B) (40µM each). Titrations were performed with 40
injections of 8 µl of SGTA in the injection syringe. C. His-Sgt2 or His-Cpr6 was isolated from
hsc82hsp82 cells expressing WT Hsp90 or Hsp90ΔMEEVD. Cell extracts were incubated with
nickel resin, and complexes were analyzed using SDS-PAGE and immunoblot analysis. The
upper panel displays the Coomassie Blue-stained gel of the resin samples, whereas the lower
panels show immunoblot analysis. Immunoblots of the lysate (L) are provided as a loading
control. The band in the stained gel that migrates below His-Sgt2 is an unknown protein that
binds nonspecifically to nickel resin.
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Figure 2.3.2 SGTA Does Not Affect Chaperone Complex Formation and Receptor Hormone
Binding in a Cell-Free System.
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Figure 2.3.2 SGTA Does Not Affect Chaperone Complex Formation and Receptor
Hormone Binding in a Cell-Free System.
A, an in vitro PR-chaperone complex reconstitution assay with serial SGTA protein
concentrations. The five purified proteins known to be required for PR to reach a hormonebinding competent conformation in vitro include Hsp90, Hsp70, Hop, Hsp40, and p23. Binding
buffer was supplemented with or without the indicated recombinant proteins and
immunoprecipitated with the PR-specific antibody, PR22. The upper panel is the Coomassie
dye-stained gel, and the lower panel is a Western blot (WB) for SGTA. Lane 1 is the molecular
weight standard and lanes 2-4 are negative controls with or without PR, the five proteins, and/or
SGTA. Increasing concentrations of SGTA from 1 to 16 µM (lanes 5-9) had no effect on PRchaperone complex assembly. B, an in vitro PR-chaperone complex reconstitution assay in
reticulocyte lysate, which contains the five proteins known to be required for PR to reach a
hormone-binding competent conformation. The right panel shows the Coomassie-stained gel and
the Western blot for SGTA. PR within the reconstituted complexes was assessed for hormone
binding using [3H] progesterone (left panel).
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2.3.3 The Q-Rich Domain is Important for SGTA Regulation of AR Activity
Previous studies in mammalian cells suggested that SGTA modulates activity through its
TPR domain based on Hsp70/90 binding (68, 69, 118). The other domains have not been linked
to a regulatory role. Therefore, we performed a sequence alignment with human SGTA and yeast
Sgt2 and found that they share the three domains: dimerization at the N-terminus, middle TPR,
Q-rich region at the C-terminus (Figure 2.3.3). In addition, they have 30% amino acid identity.
However, the C-terminus of human SGTA is significantly more glutamine-rich as compared to
the yeast homologue Sgt2. Thus, we tested SGTA truncation mutants to understand which
domains were critical for the regulation of AR activity. To assess SGTA structural domains in
AR activity, we generated β-galactosidase reporter strains in a W303a background and assayed
for receptor function in the presence of empty vector, full-length SGTA, or the truncated SGTA
expression vector. The truncation mutants were engineered according to the structural map
created by Dutta et al (125). Full-length SGTA overexpression significantly reduced AR activity
as compared with the empty vector control (Figure 2.3.4B). Deletion of half the glutamine-rich
region at the C-terminus or the dimerization domain did not have an effect in AR regulation as
compared to full-length SGTA. Elimination of the glutamine-rich region at the C-terminus and
deletion of the linker between the TPR and the Q-rich region failed to abrogate AR activity. The
effect observed was not due to receptor destabilization (Figure 2.3.4B, inset).
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Figure 2.3.3. Human SGTA and Yeast Sgt2 Amino Acid Sequence Alignment.
An amino acid comparison was made with human SGTA and yeast Sgt2 in which they share the
three domains, which are shaded and are 30% amino acid identical. At the N-terminus is the
dimerization domain, the middle TPR, and at the C-terminus a glutamine-rich region. However,
the yeast Sgt2 contains less glutamines at the C-terminus.
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Figure 2.3.4 SGTA-specific effects on AR in yeast.
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Figure 2.3.4. SGTA-Specific Effects on AR in Yeast.
A, structural map encompassing full-length and truncated domains of SGTA based on amino acid
positions. B, yeast reporter strains for AR in a W303a genetic background were transformed with
empty plasmid vector or a plasmid expressing human full-length or truncated SGTA. The cells
were treated with 5 nM DHT and assessed for receptor-mediated β-galactosidase expression.
Full length SGTA negatively regulated AR as compared to the empty vector. Elimination of half
of the glutamine rich domain at the C- terminus or the dimerization domain at the N-terminus
region had no statistically significant difference in AR activity in comparison to the full-length
SGTA. Deletion of the Q-rich region at the C-terminus failed to abrogate AR activity as
compared with the full-length SGTA. Yeast lysates were prepared and immunoblotted for AR,
SGTA, or actin as a loading control (insets).
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2.4 Discussion
SGTA binding to Hsp70/90 in mammalian cell lysates was previously documented and it
was speculated that SGTA regulates receptor function through its TPR-Hsp interaction. The
previous information available for SGTA binding to Hsp70/90 was performed in yeast and
mammalian cell lysates. In this chapter, we demonstrate a direct interaction with Hsp70 and
Hsp90 in the absence of other factors and determined the binding affinities of SGTA interaction
with Hsp70 and Hsp90 in vitro (Figure 2.3.1A,B). The measured affinity for Hsp70 binding is
two-fold higher than that for Hsp90 binding. Consistent with these results, SGTA preferentially
co-precipitated with Hsp70 in yeast (Figure 2.3.1C). In addition, SGTA modulation of Hsp70
ATPase activity was previously shown (68, 119, 188).
The specificity shown by SGTA is remarkably similar to that of FKBP52. Both proteins
have a TPR domain, which permits protein-protein interactions. However, the fact that SGTA
negatively affects receptor in yeast lacking FKBP52, and the fact that SGTA had no effect on
receptor maturation and hormone binding ability, which is regulated by FKBP52, suggest that it
is not acting through simple competition with FKBP52 for binding Hsp90. This chapter has
shown that SGTA binds Hsp70 with a two-fold higher affinity than Hsp90, which suggests that
SGTA is acting on the receptor in intermediate complexes through its interaction with Hsp70.
SGTA is known for its down-regulatory effect on AR, GR, and PR (67). Its structural
composition is comprised of three regulatory domains (66). Yeast and human SGTA share the
three domains but the yeast homologue is less Q-rich at the C-terminus (Figure 2.3.3). This
chapter has demonstrated that deletion of the Q-rich region fails to abrogate receptor function
(Figure 2.3.4). Even though this does not seem to be due to receptor destabilization as the Figure
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2.3.4 insets shows, it is important to note that this should be further investigated given that the
results could possibly be due to misfolding of the truncation mutants.
These findings present exact binding affinities of SGTA towards the Hsp70/90 proteins
and its involvement in the chaperone pathway, in which it is not required for hormone assembly
or regulation. In addition, the glutamine-rich C-terminus fails to abrogate AR activity. Further
studies are needed to continue to characterize the other pathways in which SGTA regulates
receptor activity. These pathways are critical for better understanding the role it has in prostate
cancer progression.
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Chapter 3: Identification of Global SGTA Interacting Proteins in LNCaP
Human Prostate Cancer Cells

55

3.1 Rationale
Molecular chaperone and cochaperone proteins have a dynamic role in steroid hormone
receptor (SHR) assembly, repair, and transcriptional regulation (189). SGTA was initially linked
to SHRs through a yeast-two hybrid screen with AR and a prostate cDNA library. After
functionally characterizing these interactions, they demonstrated that SGTA down-regulated AR
activity in prostate cancer cells and, based on in silico modeling, it was predicted that SGTA
interacts with AR’s EEVD-like sequence in the hinge region, thus, retaining AR in the cytoplasm
(69). Since AR, GR, and PR are members of the nuclear receptor superfamily and have highly
conserved structural domains, we sought to determine whether SGTA would regulate these
receptors as well (190). To this end, our laboratory was the first to demonstrate that SGTA
associates with PR and GR complexes through yeast-two hybrid analysis and PR reconstitution
assays in vitro (67). Thus, we hypothesized that SGTA’s regulation of AR, GR, and PR is based
on its ability to interact with Hsp70/90 via its TPR domain. Although GR and PR associated with
SGTA, the regulation posed by SGTA may not be solely in the hinge region since GR and PR do
not have an EEVD-like sequence in this region. SGTA’s association with AR, GR, and PR is
also noteworthy because these complexes are highly dynamic and were recently implicated in
prostate cancer (191).
While studies have identified SGTA as an emerging protein interactor with viruses,
neurons, protein quality control partners, and AR, the relevance of SGTA’s importance for SHR
regulation in PCA has not been studied extensively. The majority of studies identifying SGTA as
an interacting partner were conducted utilizing a yeast-two hybrid model system. For instance,
SGTA’s interaction with viral proteins such as VpU, HIV-1 Gag, NS1-Parvovirus H-1, SV40,
and SARS-CoV7a led to the understanding that SGTA is important in viral particle assembly and
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release, inhibition of viral release, and ER membrane incorporation (103, 104, 112, 145). Since
SGTA has a middle TPR domain, the first biological role was based on the idea that TPR
proteins can moderate apoptosis (192, 193). Fluorescence microscopy revealed that the full
middle TPR domain was essential to stimulate apoptotic functions based on deletion mutants
(194). On the other hand, Winnefeld et al showed that SGTA has anti-apoptotic properties in an
SGTA knock down NBE cell line (124). In light of this conflicting dataset, it appears that SGTA
displays both anti- and pro-apoptotic functions in a tissue-dependent manner. SGTA is also
responsible for cell division in which its interaction with Bag6/Bat3/Scythe can prevent mitosis
(195). All told, it is believed that SGTA can serve as a “housekeeping” protein.
SGTA also interacts with the N- terminus of myostatin (122), cysteine string protein
(CSP) (119), UbE motif of growth hormone receptor (129), TRC40 substrate Sec61β (132), and
SV40 (145). These interactions have mainly been observed through yeast-two hybrid studies,
which showcase SGTA’s multifaceted roles. A list of published SGTA interacting proteins is
shown in Table 1.
Proteomic approaches have significantly advanced many scientific fields through their
sensitivity and unbiased method of detecting proteins. While our current understanding of
molecular chaperone association in prostate cancer is evolving, there remains a need to
understand co-regulators within androgen receptor signaling pathways possibly contributing to
prostate cancer progression. Based on this idea, we used a proteomic approach to discern global
protein interactors of SGTA in LNCaP prostate cancer cells. Although there is an increasing
amount of known SGTA interactors in noncancerous settings, mainly through yeast-two hybrid
screens, little is known about SGTA’s interactors in prostate cancer cells.
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Our initial hypothesis centered on SGTA working in unison with unidentified proteins
known to promote PCA progression through links in AR signaling pathways. In order to test this
hypothesis, we performed a top-down proteomics approach using tandem affinity purification in
LNCaP PCA whole-cell lysates, and then functionally characterized these interactions.
3.2 Materials and Methods
3.2.1 Construct of SGTA-6XHis-Gly-FLAG
Using PCR recombinant techniques, a full-length SGTA cDNA was tagged at the Nterminus with a 6X His-tag followed by tagging with a FLAG (DYKKDDDDK) epitope. The
construct was cloned into a mammalian expression vector (pCI-Neo), which contains a CMV
promoter and a Neomycin marker using XbaI and XmaI restriction enzymes.

3.2.2 MEF52KO Receptor- Mediated Reporter Assay
Mouse Embryonic Fibroblasts (MEF52KO) is a cell line that has been used to determine
SGTA down-regulation of AR (67). MEF52KO cells were maintained in Minimal Essential
Medium (MEM) supplemented with 10% Fetal Bovine Serum (FBS) at 37°C in a 5% CO2
atmosphere. Cells were plated at a 1x105 density/ well in a 6-well tissue culture plate. Cells were
transfected using Lipofectamine Reagent 2000 (Invitrogen) and followed standard procedures
once 60-80% confluence was reached. The plasmids used for these assays were a hormoneresponsive firefly luciferase reporter (400 ng per well), a mammalian expression vector (pCINeo) expressing wild type SGTA and tagged SGTA (800 ng per well), and a constitutive βgalactosidase expression plasmid that served as a transfection control (50 ng per well). The
transfection was performed at a DNA (µg) to lipofectamine ratio of 1:3 in MEM-EBS lacking
FBS. Four hours post-transfection, the medium was changed to MEM supplemented with 10%
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Charcoal-Treated (CT) FBS. Twenty-four hours after transfection, the cells were treated with
100 nM dihydrotestosterone (DHT). Sixteen hours later, the cells were lysed using 100 uL of
Mammalian Protein Extraction Reagent (M-PER) with a Protease Inhibitor Cocktail without
EDTA (Thermo) and incubated at room temperature for ten minutes. Next, the cells were scraped
and transferred to a cold microfuge tube. The cells were then centrifuged at 135Xg at 4°C for 20
minutes. The supernatant was used directly in the luciferase and β-galactosidase assays. To
measure luciferase activity, 40 µL of sample and 100 µL of luciferase assay reagent (Promega)
were added to individual wells on an opaque 96-well plate and the light emission was measured
in a luminescence plate reader (Gen5 BioTek) immediately. For β-galactosidase activity, 10 µL
of sample was incubated with 100 µL of Tropix Gal-Screen reagent (Applied Biosystems) in a
96-well plate and incubated for 2 hours at room temperature. β-galactosidase was measured
using a luminescence plate reader (Gen5 BioTek). To measure any transfection efficiency
differences, the data was normalized by dividing the relative light units (RLU) by βgalactosidase activity. This experiment was performed in duplicate and three independent
experiments were performed (156).
3.2.3 Tandem Affinity Purification in Human LNCaP Cells
LNCaP cells are an early stage PCA cell line that was derived from a 50-year old
Caucasian male. These cells serve as a representation of an early stage prostate cancer setting,
thus serving as an excellent model to look at SGTA interacting partners (196). LNCaP cells were
maintained in RPMI-1640 Medium supplemented with 10% FBS at 5% CO2 and 37°C. LNCaP
cells were plated in a tissue culture petri dish at a density of 8.0x105 cells/dish. After 48 hours, at
60-80% confluence, cells were transfected using Lipofectamine 2000 reagent (Invitrogen) and
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manufacturer’s procedure was followed. The transfection was performed using 800 ng of
mammalian expression empty vector (pCI-neo) as our control, and 800 ng of tagged SGTA was
also transfected with RPMI-medium lacking FBS. 4-6 hours post-transfection, the medium was
changed to RPMI with 10% FBS. After 48 hours, the cells were washed with cold PBS three
times and 1 ml of ice-cold lysis buffer (50 mM Tris-HCl pH 7.6, 10 mM NaCl, 0.5% NP-40,
Protease Inhibitor Cocktail-EDTA Free (Thermo)) was added and incubated for 30 minutes. The
cells were scraped and transferred to a microcentrifuge tube (AMGDAD) and centrifuged at
135xg for 30 minutes at 4°C. The supernatant was used immediately for nickel purification. 10%
of supernatant was used for verification of expression of tagged SGTA and wild type SGTA
vector via Western blot using anti-hSGTA 1:1000 (ProteinTech), anti-OctA (FLAG) Probe (D-8)
sc-807 1:1000 (Santa Cruz Biotechnology). The tandem affinity purification was performed in
batch. The cell lysate was incubated with 100 µL of nickel beads (4 vs 16 hrs) with 1 mg of cell
lysate and a final volume of 20 mM of Imidazole was added to the reaction at 4°C with gentle
rotation. The resin-lysate was washed 5 times with wash buffer (25 mM Tris-HCl pH 7.4, 150
mM NaCl, 0.1% NP-40, 20 mM Imidazole) we ensured the buffer was in a pH of 7.0. The
elution was performed with 275 µL with elution buffer pH 8.0 (25 mM Tris-HCl pH 7.4, 150
mM NaCl, 300 mM Imidazole). The FLAG co-immunoprecipitation was performed following
Krogan et al protocol (197). The eluate was further analyzed using 40 µl of Anti-FLAG M2
Affinity gel (Sigma) and left overnight with gentle rotation at 4°C. The next day, the resin celllysate was centrifuged at 8200xg for 30 seconds and incubated 2 minutes before handling the
samples. The supernatant was carefully removed and the resin was washed 5 times with cold
lysis buffer followed by one wash with lysis buffer without detergent. The samples were eluted
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with 40 µL of 100 µg/ml 1X FLAG peptide (Sigma F3290), 0.05% RapiGest (Waters) in 50 mM
Tris-HCl pH 7.6, 150 mM NaCl.
3.2.4 Sample Preparation for LC-MS/MS
LNCaP eluate samples were prepared for LC-MS/MS proteome analysis using the filter
aided sample preparation (FASP™) Protein Digestion Kit (Expedeon) and modified accordingly.
Samples were digested using 1 µg of SIGMA Trypsin Proteomics Grade and incubated overnight
at 37°C. Digested samples were eluted into a clean collection tube with 0.1% formic acid. The
final solution was concentrated in the vacufuge and frozen until LC-MS/MS analysis.
The complex peptide mixture from individual samples were then analyzed by
LC/MS/MS at UTEP’s Biomolecule Analysis Core Facility. Samples were loaded onto a pico
C18-12 cm media (Luna, New Objective). Once loaded, the column was moved in-line with a
U3000 HPLC (Dionex, subsidiary of Thermo Fisher Scientific) split to obtain ~300 nL/min flow
rate over the nano-analytical column. The resolving column was housed in a nanospray sourse
(Proxeon, Thermo Fisher Scientific) attached to a QExactive mass spectrometer (Thermo Fisher
Scientific). An automated 22 h LC-MS/MS run was programmed into Xcalibur (Thermo Fisher
Scientific) and each sample was analyzed with a separation scheme consisting of eleven salt
pulses followed by a 2 hour C18 separation. During each analysis and all sample runs, the
QExactive settings were as follows: the normalized collision energy for HCD was 28eV, a full
scan resolution of 70,000 K from 400-1600 m/z, a HCD MS/MS resolution of 17,500 with an
isolation width of 3 m/z, and the dynamic exclusion was set at 15 seconds. Peptides were not
excluded based on charge state and 1 microscan for both full and MS/MS scans were acquired.
All MS and MS/MS data were acquired in profile mode.
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3.2.5 Proteome Informatics
All resultant MS/MS spectra from individual 24 hour runs were searched with Proteome
Discoverer 2.0 (Thermo Fisher Scientific) and filtered via reverse database searching with
maximum false positive rate of 0.5. The Proteome Discoverer settings were as follows: HCD
MS/MS, included a fixed modification for carboxyamidomethylated cysteines, a variable
modification for urea carbamylation of arginine and lysine residues, fully tryptic peptides only, 4
missed cleavages, a precursor mass tolerance of 10 ppm and a fragment mass tolerance of 0.6
Da. Only proteins identified with two fully tryptic peptides from a 22 run were considered for
further analysis. Tandem MS/MS spectra were searched against a combined protein database of
Homo sapiens.
Hierarchical clustering was performed on the resultant filtered proteome dataset using
Cluster 3.0. Clustered data were depicted graphically (Heatmap). GO terms were used to
generate the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) network for
interacting partners graphic representation (198).

3.2.6 Co-Immunoprecipitations in LNCaP Cells
For the Co-IP experimentation, 200 µL of magnetic beads (Thermo Scientific) suspended
resin per assay condition was added to microcentrifuge tubes, tubes were placed into the magnet
and supernatant was removed. Resin beads were washed twice in ice-cold TBS and resuspended
in 500 µL 0.1%Milk in TBST. 6 µl of SGTA antibody (Santa Cruz) was added to the mixture
and incubated for two hours at 4°C. Meanwhile, the cells were washed three times with cold PBS
and incubated with lysis buffer (150 mM NaCl, 50 mM Tris, 0.1% NP-40, Protease Inhibitors)
for 30 minutes. The cells were then transferred to a microcentrifuge tube and centrifuged at
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maximum speed at 4°C for 20 minutes. The cell lysate was pre-cleared twice using the magnetic
beads (Thermo). The pre-cleared cell lysate and antibody-resin complex was incubated for 3
hours at 4°C with gentle shaking. The complex was then washed 5 times with TBST with 5
minute incubation intervals. Then 50 µL of 4X sample buffer and β-mercaptoethanol was added
to each sample including the inputs. Proteins were separated by electrophoresis, transferred to a
PVDF membrane (Millipore) and immunoblots were performed. 10% of supernatant was used
for verification of expression of SGTA via Western blot using anti-hSGTA 1:1000 (ProteinTech)
and human PRDX1 1:2000 (ProteinTech).
3.2.7 FLAG In Vitro Assays
For the FLAG-pull down assay, ANTI-FLAG® M2 Magnetic beads (Sigma-Aldrich)
were used and followed manufacturers protocol. Briefly, 20 µL of packed gel volume were
thoroughly resuspended and equilibrated with 5 packed gel volumes of TBS (50 mM Tris-HCl,
150 mM NaCl, pH 7.4). Beads were washed twice with TBS. The purified proteins were added
alone or in conjunction. 2 nM/500µL of recombinant hSGTA (67), PRDX1-FLAG (Origene)
was incubated with the beads for 2 hours at 4°C with gentle mixing. Upon completion of
binding, the magnetic beads were collected using the magnetic separator. The resin beads were
washed with TBS three times. The elution performed by adding 50 µL of 4X sample buffer and
β-mercaptoethanol was added to each sample including the inputs. Proteins were separated by
electrophoresis, transferred to a PVDF membrane (Millipore) and immunoblots were performed.
10% of supernatant was used for verification of expression of tagged SGTA and wild type SGTA
vector via Western blot using anti-hSGTA 1:1000 (ProteinTech), anti-OctA (FLAG) Probe (D-8)
sc-807 1:1000 (Santa Cruz Biotechnology) and anti-human PRDX1 1:2000 (ProteinTech).
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3.2.8 Generation of SGTA Knock Out HeLa and 22Rv1 Human Cells
The CRISPR/Cas9 system has become a widely used biotechnology due to its ability to
knock out genes from cells (199). Here, we exploited this system and utilized the Santa Cruz
Biotechnology SGTAKO plasmids to knock out SGTA in HeLa and 22Rv1 cell lines. The SGTA
CRISPR/Cas9 KO (sc-404399) plasmid was obtained with the SGTA HDR plasmid (sc-404399HDR). Briefly, both cell lines were seeded at 2.0x106 and incubated for 24 hours prior
transfection. The following day, cells were transfected in a medium lacking FBS with equivalent
ratios of DNA (1 µg) with Lipofectamine transfection reagent and was used at a 1:3 plasmid to
DNA ratio. 4 hours-post transfection the medium was changed to normally used medium to
culture the cells (+10%FBS). Selection was started for two weeks in which, 72 hours posttransfection, 3 µg/µl of Puromycin (InvivoGen) was added to the cells and the medium was
changed every 2-3 days. The cells were then selected based on colony formation and further
expanded. Successful colony selection was then confirmed via Western Blot and probing against
human SGTA. The cells were maintained and cultured with their respective mediums used for
maintenance without antibiotic.
3.2.9 Receptor-Mediated Reporter Assay
In a 6-well plate 3.0x106 cells were plated using medium supplemented with 10% FBS.
The following day, the cells were checked for complete attachment and once they reached a 6080% confluence, transient transfection was performed using Lipofectamine 2000 Reagent
(Invitrogen) according to manufacturer’s instructions. The transfection was performed in
duplicates for 4 hours using an equal amount of DNA and a DNA to Lipofectamine ratio of 1:3
in medium lacking FBS. The following plasmids were mixed as follows: 400 ng of pT81
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(American Type Culture Collection, Manassas, VA) hormone-responsive firefly luciferase
reporter, 50 ng of constitutive pCMVβ β-galactosidase expression plasmid (Clonetech, Mountain
view, CA), which served as our transfection control, 800 ng of mammalian expression vector
pCI-neo (Promega, Madison, WI), expressing human AR (note: no exogenous AR was utilized in
22Rv1 SGTAKO cells), SGTA and PRDX1. pCI-neo empty vector was used as a control, SGTA
and PRDX1 were mixed alone or in combination. Four hours post-transfection the medium was
changed to 10% Charcoal Treated FBS. Twenty-four hours after transfection, the cells were
treated with 1 nM DHT for 16 hours.
The cells were washed three times with PBS and incubated with 100 µL of M-PER
(Pierce, Rockford, IL) supplemented with Complete EDTA-free Mini Protease Inhibitor
(Thermo) incubated for 10 minutes with rocking. The cells were then scraped and transferred to a
microcentrifuge tube. The cells were spun using a microcentrifuge to remove debris at 15,000
rpm for 20 minutes at 4°C. 40 µL of the cell lysate with 100 µL of luciferase assay reagent
(Promega, Madison, WI) were mixed in a single well for each sample on a 96-well plate, which
was used to measure luciferase expression and read immediately in a microplate luminometer
(Luminoskan Ascent, Thermo Labsystems). 10 µL of the cell lysate with 100 µL of Gal-Screen
Reagent (Tropix, Bedford, MA) was used to measure β-galactosidase expression. This mixture
was performed in a 96-well plate and incubated for two hours at room temperature, followed by
quantification in the microplate luminometer. Luciferase RLU/β-galactosidase RLU were
normalized and the transfection efficiency was demonstrated in graphical form utilizing
GraphPad Prism software. The data is presented as the mean (+/- standard deviation) of duplicate
samples and at least three independent experiments were performed.
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3.2.10 Mammalian Cell lines
LNCaP cells were maintained using RPMI + 10% FBS. 22Rv1SGTAKO cells were
maintained using RPMI-EBSS + 10% FBS + 1% NEAA + 1% NaPyr. For LNCaP and 22Rv1
cells transfections were performed with RPMI-EBSS lacking FBS. Upon transfection, 22Rv1
cells were maintained in RPMI-EBSS + 10% CT-FBS + 1% NEAA + 1% NaPyr. HeLa
SGTAKO cell lines were maintained in MEM-EBS 10% FBS and upon transfection, the cells
were changed to MEM-EBSS + 10% CT-FBS.

3.3 Results
3.3.1 A Schematic Representation of Analyzed LC-MS/MS Samples
To identify unknown protein interactors that preferentially co-precipitate with SGTA, we
performed a label-free spectral count quantitative proteomics and utilized it to compare SGTA6XHis-FLAG tag with an empty vector in LNCaP Cells. An overall visual representation of the
approach can be seen in Figure 3.3.1A in which LNCaP cells were transiently transfected with
either an empty vector or SGTA tag. The cells were lysed and purified first using a batch nickel
purification followed by a FLAG Co-IP. The eluates were trypsin digested using a FASP Kit.
The digested samples were further analyzed by LC-MS/MS. To affirm that tagged SGTA would
not alter SHR function, we conducted luciferase reporter assays in MEF52KO. Figure 3.3.1B is a
representative of at least three separate assays. The vehicle control demonstrates that the activity
being measured is hormone-induced receptor activity. The data demonstrate that there is no
significant difference between wild type and tagged SGTA. LNCaP cell lysates were
successfully transiently transfected as shown in Figure 3.3.1C. Cells were lysed and expression
of wild type and tagged SGTA were observed. Transfection did not alter the cells because the
band in the vector indicates the presence of SGTA due to the endogenous expression in LNCaP
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cells. Furthermore, there is no band seen in the vector with anti-FLAG in the eluates. The 3 hour
versus the overnight incubation demonstrated a similar level of SGTA. These eluates were sent
for further analysis in the LC-MS/MS.
3.3.2 SGTA Associated Proteins Visualized in a Heat Map
To assess preferential binding interactors with SGTA, a hierarchical clustered analysis
was performed using SAINT analysis on the spectral count generated from PD 2.0. The resulting
heat map in Figure 3.3.3 indicates sets of genes expressed predominantly with SGTA based on a
0.5% FDR. Two biological replicates with four technical replicates within each biological
sample were analyzed. A total of 31 genes associated with SGTA in both biological replicates
and in both conditions (3 vs 16 hours). Interestingly, a significant log fold change demonstrated
that SGTA has a preference to the B2R4P2 gene, which was present in all conditions suggesting
this interaction can be both transient and strong. The B2R4P2 gene encodes Peroxiredoxin-1
(PRDX1) protein. PRDX1 has been previously functionally associated with the AR pathway by
interacting with and enhancing AR transactivation (200, 201). Within this cluster, SAINT
analysis revealed enrichment with the chaperones Hsp70 and Hsp90, validating our interactors
list since previous reports have established these interactions. General housekeeping proteins
such as ribosomal proteins were also present in high abundance. A limitation with ribosomal
proteins can be their abundance in Co-IP experiments since they are able to “stick” to resin and
many proteins. Even though it has been established that SGTA contributes to protein quality
control (Refer to Section 1.4.3 for details), we decided to pursue PRDX1 based on its relevant
functional biological role with AR.
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3.3.3 SGTA’s String Network
From the resulting heat map (Figure 3.3.2), the associated gene sets were subsequently
classified using GO terms that convey genes to biological functions. STRING interaction
network in Figure 3.3.3 illustrates the association of SGTA with the total interacting proteins that
were pulled out from the QSPEC analyzed files. The associations are made based on reported
interactions in the literature. In the STRING network, a cluster of ribosomal proteins is observed
and no known link with SGTA has been established. In addition, Hsp90 forms a complex with
SGTA in which previous groups and ours have established this interaction. Moreover, the
network analysis reported 14 proteins that are not ribosomal or chaperones to be SGTA binding
partners (Figure 3.3.4). Interestingly, PRDX1 was associated previously with Hsp90 but no
direct link with SGTA nor Hsp70 has been reported.
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Figure 3.3.1 Schematic Representation of Proteomic Workflow.
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Figure 3.3.1. Schematic Representation of Proteomic Workflow.
A. LNCaP Cells were plated and upon 70% cell confluence, transfection of the empty vector
(pCI-Neo) and SGTA-6XHIS-FLAG was performed using Lipofectamine 2000. Cells were then
lysed and a nickel purification was performed followed by a FLAG-Co-IP overnight. The eluates
were Trypsin digested using a FASP Kit and analyzed by LC-MS/MS. Quantification of the
spectral count was performed and networks were generated and assessed. B. MEF52KO cells
were used to perform a luciferase reporter assay. In comparison to the empty vector (pCI-neo)
wild type SGTA and tagged SGTA did not alter receptor activity. C. SGTA protein expression is
verified using immunoblots for the input and eluate experiments in both conditions 3 hours vs
overnight.
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Figure 3.3.2 Heat Map of SGTA Associated Protein Network
SAINT analysis was performed on spectral count and GO term enriched values with a 0.5% FDR
were used to generate the heat map. 31 proteins preferentially bound SGTA in the two biological
replicates and four technical replicates within each biological set.
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Table 2: Description of Identified Protein Interactors of SGTA

Number
1

Prey Gene
Name:

2

RPS3_HUMAN
B7Z437_HUMA
N

3

RPL24_HUMAN

4

B7Z2S7_HUMA
N

5
6
7
8
9

RPS16_HUMAN
RPL27A_HUMA
N
A8K7H3_HUMA
N
B4DR68_HUMA
N

10

TRA1_HUMAN
B4DMF5_HUMA
N

11

ANXA2_HUMAN

12

RPL22_HUMAN

13
14

ANXA1_HUMAN
B4E1H9_HUMA
N

15

RPS8_HUMAN

16
17

RPL9_HUMAN
HNRNPAB_HU

Protein Name:
Ribosomal protein S3
40s
cDNA: FLJ53435,
highly similar to Ezrin
60S ribosomal protein
L24
cDNA: FLJ58499,
highly similar to
Radixin
Ribosomal protein S16
40s
60S ribosomal protein
L27
cDNA: FLJ77670,
highly similar to H.s.
ribosomal protein s15a
Heat shock protein
75kDa, mitochondrial
Tumor Rejection
Antigen aka HSP90B
Glutamate
dehydrogenase

MW
(kDa)

Biological Function:

27

Translation

51

Cytoskeletal Structure

18

Translation

53

Translation

17

Translation

17

Translation

15

Translation

80

Chaperone

92

Protein Folding

57

Metabolism
Ca regulated
membrane binding
protein

Annexin A2
60S ribosomal protein
L22

39

Annexin A1
phosphoglycerate
kinase
40S ribosomal protein
S8
60S ribosomal protein
L9
Heterogeneous

39

Translation
Calcium/phospholipidbinding protein which
promotes membrane
fusion and is involved
in exocytosis.

35

PTM

24

Translation

22
36

Translation
Transcription
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15

MAN

18

A8KA83_HUMA
N

19

B3KXZ4_HUMA
N

20

RPS23_HUMAN

21

A8K7N0_HUMA
N

22

RPL13_HUMAN

23

GNB2L1_HUMA
N

24

B4DN41_HUMA
N

26

PRKAA1_HUMA
N
A8K9J7_HUMA
N

27

B4DDF5_HUMA
N

28

RPS21_HUMAN

25

30

B4DMT5_HUMA
N
GLT25D1_HUM
AN

31

B2R4P2_HUMA
N

29

nuclear
ribonucleoprotein A/B
27

Protein Transportation
and membrane
organization

91

DNA Replication

16

Translation

24

Translation

24

Translation

35

Translation, Cell
division

68

ATP Binding

64

PTM-Cell Energy
Metabolism

Histone H2B
cDNA: FLJ53435,
highly similar to DNA
replication licensing
factor MCM7
40S ribosomal protein
S21
Eukaryotic
translational initiation
factor 3 subunit F

14

DNA Binding

73

DNA Replication

9

Translation

33

Translation

GLT25D1 protein
cDNA: FLJ53435,
highly similar to H.s.
peroxiredoxin 1

26

LPS Biosynthesis

22

Transcription

cDNA: FLJ78586,
similar to HS VAMP
cDNA: FLJ53435,
highly similar to DNA
replication licensing
factor MCM2
40S ribosomal protein
S23
cDNA: FLJ53435,
highly similar to H.s.
ribosomal protein L14
60S ribosomal protein
L13
Guanine nucleotidebinding protein subunit
beta-2-like 1
cDNA: FLJ53435,
highly similar to
Probable ATPdependent RNA
helicase DDX5
5'-AMP-activated
protein kinase catalytic
subunit alpha-1
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Figure 3.3.3 SGTA STRING Network Analysis
The STRING network analysis was generated based GO terms and on the total proteins
generated by the heat map. The analysis depicts the known interactions of Hsp70 and Hsp90 to
SGTA as observed in a triangular fashion. A ribosomal clustered analysis is also present. The
other unknown protein interactors of SGTA have not been previously published.
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Figure 3.3.4 SGTA Non-Ribosomal STRING Network Analysis
A STRING network analysis generated from the heat map based on GO terms lacking ribosomal
proteins cluster.
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3.3.4 PRDX1 Interacts with SGTA in LNCaP Cells and In Vitro
Previous studies in mammalian cells suggested that PRDX1 is an AR modulator based on
its ability to enhance transactivation and allow AR to facilitate binding to DHT with higher
affinity. Thus, we assessed SGTA’s association with PRDX1 in LNCaP cells and in vitro using
human purified recombinant protein. To validate the interaction demonstrated by the Heat Map
(Figure 3.3.2), we co-immunoprecipitated endogenous SGTA with PRDX1 from LNCaP prostate
cancer cell lysates (Figure 3.3.5A). PRDX1 co-immunoprecipitaed with SGTA and no visible
interaction was seen in the negative control IgG. To further validate this interaction, we assessed
the ability of SGTA to interact directly with PRDX1 in vitro in the absence of other proteins.
Recombinant human SGTA co-precipitated with recombinant FLAG-tagged PRDX1 in a cellfree system, but failed to precipitate on the FLAG resin in the absence of other proteins (Figure
3.3.5B). These interactions demonstrate that SGTA directly interacts with PRDX1.
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Figure 3.3.5 Interactions with PRDX1 and SGTA
A A co-immunoprecipitation was performed in LNCaP cell lysates to detect SGTA and PRDX1
interaction. SGTA was co-immunoprecitated and blots probed for SGTA and PRDX1. Inputs are
shown at the bottom. B In vitro FLAG-pull down assays were performed with purified,
recombinant human PRDX1-FLAG alone, and SGTA-HIS tag alone, and in combination.
Proteins were visualized on Western Blots using primary antibodies specific to human SGTA,
PRDX1, and FLAG.
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3.3.5 Effects of SGTA on PRDX1 Regulation of AR Function
Our previous data indicate that SGTA and PRDX1 have a direct interaction. SGTA is a
specific negative regulator of AR, GR, and PR. Interestingly, PRDX1 is a positive regulator of
AR in prostate cancer cells (200). To functionally assess whether SGTA and PRDX1 are relevant
interactors, we developed SGTA knockout HeLa and 22RV1 cell lines using the CRISPR/Cas9
system. We assessed the effects of SGTA and PRDX1 co-expression on exogenous AR activity
in HeLa cells (Figure 3.3.6A) and endogenous AR 22Rv1 (Figure 3.3.6B) SGTAKO cell lines.
Receptor-mediated luciferase assays were performed in the presence of empty vector or plasmids
expressing SGTA and PRDX1 either alone or in combination. SGTA expression alone
significantly reduced receptor activity, PRDX1 expression alone significantly enhanced receptor
activity, and in the presence of SGTA and PRDX1 receptor activity was unchanged. Thus, in the
presence of SGTA, PRDX1-mediated potentiation was completely abrogated. Immunoblots for
SGTA, PRDX1 and the loading control GAPDH were performed on the samples used in the
luciferase assays (insets). Interestingly, the same trend has been observed with the TPRcontaining FKBP52, which is a positive regulator of AR, GR, and PR. This data suggests SGTA
is a potent inhibitor of receptor function and has antagonistic properties.
The data indicate that this co-regulatory mechanism is pertinent in a prostate cancer
setting as performed in the 22RV1 SGTAKO cells. This cell line is known to have the
endogenous splice variant ARV7 that constitutively activates AR function. An interesting
observation was made in Figure 3.3.6B, in which PRDX1 up-regulated endogenous AR activity
with no DHT present. In addition, it can be noted that there was an increasing up-regulation of
PRDX1 with increasing concentrations of DHT.

78

Figure 3.3.6 Effects of SGTA on PRDX1 Regulation of AR Function in HeLa and 22Rv1 SGTA
KO Cells
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Figure 3.3.6 Effects of SGTA on PRDX1 Regulation of AR Function in HeLa and 22Rv1
SGTA KO Cells
A. AR-mediated luciferase assay in HeLa SGTA KO cells in the presence of an empty vector,
SGTA, PRDX1, or SGTA and PRDX1 combined with or with 0, 100 pM or 1 nM of DHT. AR
potentiation by PRDX1 was observed in the presence of DHT. AR activity was suppressed by
SGTA alone, and in combination, SGTA inhibits PRDX1 enhancement of AR activity.
Immunoblots for AR, SGTA, PRDX1, SGTA, and GAPDH in HeLa SGTAKO observed in the
insets. B. Endogenous AR activity was measured with a luciferase reporter assay in 22Rv1
SGTAKO cells in presence or absence of an empty vector, SGTA, PRDX1, or SGTAA and
PRDX1 in conjunction with 0, 100 pM, or 5 nM DHT. SGTA decreased AR activity, PRDX1
potentiated and in combination, AR remained unchanged. Upper panels demonstrate the
immunoblots against human AR, SGTA, and PRDX1.
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3.4 Discussion
Previously, we utilized yeast two-hybrid to understand SGTA’s association with GR and
PR complexes (67). Although SGTA does not affect chaperone complex formation and receptor
hormone binding in vitro (Chapter 2), it remains ubiquitously expressed predominately in human
tissues relevant to reproductive processes. This also led to the belief that there are other
mechanisms in which SGTA acts, which made it clear that a proteomic approach in LNCaP cells
is applicable. The use of a label-free quantitative proteomic screen in LNCaP cells revealed
SGTA significantly associates with Peroxiredoxin I, Hsp70, and Hsp90 in the conditions (3 vs 16
hours) tested. Hsp70 and Hsp90 have been previously reported to bind with SGTA and in our
study, we were able to observe the presence of these proteins suggesting that our proteomic
screen was reliable.
Our heat map revealed that PRDX1 had a high value of spectral count in all the
conditions tested (Figure 3.3.2). We validated that SGTA directly interacts with PRDX1 and in
LNCaP cells (Figure 3.3.4). PRDX1, a 22kDa protein, is known for its antioxidant properties and
its ability to potentiate AR. Our data firmly establish the suppressive effect of SGTA on AR and
the potentiation of PRDX1 in AR in both HeLa and 22Rv1 SGTAKO cells. Receptor-mediated
reporter studies in prostate cancer cells have contributed to the current knowledge of progression
and drug targeting. Interestingly, in an SGTAKO cell line, PRDX1 was able to potentiate AR
activity, however, when co-expressed, SGTA abrogated PRDX1’s ability to potentiate AR.
This study is the first to demonstrate SGTA’s interaction with PRDX1 and the
antagonistic effects it possesses with AR activity. The exact mechanism by which SGTA and
PRDX1 mediate AR remains to be characterized, but the results of this chapter suggest that
SGTA can antagonize PRDX1 regulation of AR activity.
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Chapter 4: Validation and Application of a Four-Hour Yeast Bioassay for
Screening Estrogenic Activity in Human Pregnant Female Urine
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4.1 Rationale
Multiple studies have previously utilized S. Cerevisiae as a tool to identify and
functionally characterize steroid hormone receptors (185), and to screen wastewater (184) and
sediment samples in aquatic systems (202). Other assays such as the nAES assay has been used
for the same purposes (203). As aforementioned, our laboratory previously developed a modified
yeast estrogen screen to assess estrogenic activity in samples in a physiologically relevant
timeframe. While the physiological relevance of the assay time (only a two-hour hormone
treatment before cell lysis) was an important factor for the study of steroid hormone receptor
signaling mechanisms including the characterization of SGTA functional domains, it was also
realized that the short assay time and sensitivity of the assay were ideal for application to
environmental samples. Thus, our group previously published the modified 4-hour yeast
bioassay for the direct measure of estrogenic activity in wastewater without the need for sample
extraction, concentration and sterilization. Prior to the studies conducted here, the four-hour
yeast bioassay has only been applied to water, sediment, and herbal extract samples. Since then,
it has been established that human urine provides another noninvasive manner to detect
endocrine disrupting chemicals, which alter estrogenic activity (204). The ability of the yeast
bioassay to directly detect estrogenic activity in environmental samples at picomolar
concentrations suggests that this assay could also be applied to urine samples. Given the short
assay time the yeast would only need to be grown directly in the presence of the urine for a 2hour period minimizing the chance of cellular toxicity. Thus, we hypothesized that the four-hour
yeast bioassay could be used as a tool to directly assess estrogenic activity in urine samples
without the need for extraction. In order to test this hypothesis we employed the 4-hour yeast
bioassay for the detection of expected estrogenic "spikes" in human pregnant female urine.
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Estrogens bind to ERα/β, which are present in females and males, to mediate cellular
functions important for cell differentiation and growth (205). Known as the ‘female’ hormone,
these estrogens along with other hormones exert multiple functions throughout pregnancy
allowing for development, maturation, and protection of the fetus (206, 207). Estrogens are the
natural ligands of the estrogen receptor and are divided in three classes: estrone, estradiol, and
estriol (208). In the case of pregnancy, estradiol is the most potent and common (209). The first
trimester is characterized by an influx of hormones such as estradiol and progesterone. In the
second trimester, estradiol levels continue increasing until reaching an apex during the third
trimester. Estradiol is the major circulating estrogen in the urine and thus can be measured as a
metabolite (210-212). Here, we used a recombinant yeast-based assay to screen for estrogenic
activity in human urine. The convenience of this assay is highlighted by the rapid growth rate of
yeast, relative low-cost, and highly conserved regulatory mechanisms between yeast and human
in this system. Thus, the assay could serve as a low-cost, invaluable research tool for the
monitoring of estrogen levels in urine from a wide variety of higher vertebrate species.
4.2 Materials and Methods
4.2.1 Urine Preparation
Normal human urine was purchased from Innovative Research Biologicals and stored in
the -80°C until further use. The urine was freshly collected from single donors according to FDA
regulations. Female donors were in their first, second, or third trimester during pregnancy. For
the negative control urine from all three trimesters, dextran-coated charcoal was used to remove
endogenous estrogens, growth factors, and cytokines from the urine. The urine was stripped
using 200 mg/10 mL of dextran-coated Charcoal (Sigma C:6241) and was incubated overnight at
4°C with gentle shaking. The following day, the charcoal was removed by cold (4°C)
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centrifugation 2000xg for 15 minutes and the supernatant was removed carefully by aspiration.
The charcoal-treated urine was used immediately for the yeast bioassays.
Given that estrogen metabolites within the urine can be conjugated after phase II
metabolism, we also assessed the importance of pre-treating with deconjugating enzymes prior to
assay. To deconjugate estrogen metabolites, urine was treated with β-Glucuronidase and
sulfatase enzymes. 1 Fishman unit liberated 1.0 µg of phenolphthalein from phenolphthalein
glucuronide per hour. The urine was treated with 1000 units/mL for 30 minutes at 37°C and used
immediately for yeast bioassay.
4.2.2 Yeast Reporter Assay
For details of the basic receptor-mediated reporter assay refer to section 2.2.3.The fourhour yeast bioassay (Figure 4.3.1) was modified from (184). Briefly, the parent strain was cotransformed with a TRP-marked constitutive human ERα expression plasmid (pG/ER) and a
URA3-marked estrogen-inducible β-galactosidase reporter plasmid (pUCΔSS-ERE, both
plasmids generously provided by Didier Picard, University of Geneva) and maintained in
synthetic complete media lacking uracil and tryptophan (SC-UW). For all assays, the yeast were
cultured overnight in SC-UW at 30°C in a shaking water bath incubator (Figure 4.3.1). The
following day, the yeast cells were measured and diluted to an optical density of 0.08 at 600 nm
and incubated until the optical density reached to 0.1. The yeast culture measured in log phase
was aliquoted into 14 ml-snap cap tubes at 1 ml per tube and centrifuged at 2000rpm for 3
minutes. The yeast cells were resuspended with 1 ml of a mixture containing 750 µL of urine
(CT/enzyme treated/none) and 250 µL of 4X concentrated SC-UW for each assay performed.
The culture was incubated for two hours at 30°C shaking incubator. 100 µL from each culture
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was then transferred to an opaque 96-well plate and substrate was added. A standard 17βestradiol dose response curve was performed in parallel by "spiking' negative control urine with
the indicated concentrations of 17β-estradiol. The standards were prepared by diluting 17βestradiol into distilled, deionized water and handled in the same manner as urine samples. For the
“plate” assays, 100µL per well of the logarithmic phase yeast culture was added to the opaque
96-well plate. 1 µL of urine (CT/enzyme treated/none) was added and incubated for 2 hours in a
30°C incubator. After a 2 hour incubation period, 100 µL of Tropix Gal-Screen in Buffer B
(Applied Biosystems, Foster City, CA) was added to each well, and the wells were covered and
further incubated for 2 hours at room temperature. The chemiluminescent signal was detected
using a Luminoskan Ascent microplate luminometer (Thermo Fisher Scientific Inc., Waltham,
MA).
4.3 Results
4.3.1 Human Urine Yeast BioAssay
Our laboratory and others have extensively utilized yeast-based methodology for the
functional characterization of steroid hormone receptor-associated cochaperones (49, 67, 90,
156, 185). Given the utility of this assay in assessing SHR function and regulation, we reasoned
that this assay could also be employed to assess hormone activity in human urine samples. A
graphic illustration of the methodology tested is described in Figure 4.3.1. Similar to the yeast
bioassay described by Balsiger et al. (184), in 4 hours the assay can be performed to analyze the
urine samples with minimal sterilization and sample preparation time. The log-phase yeast cells
are incubated with urine that has been previously diluted to a ratio of 1:4 in 4X-concentrated
yeast medium for 2 hours in a shaking incubator at 30°C prior to addition of β-galactosidase
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substrate (Figure 4.3.1, left side). The cells were further incubated for 2 hours for maximal
chemiluminescent signal and read by a microplate luminometer. An advantage of our yeast
bioassay is the minimal amount of urine needed, in which, 300 µl of urine sample was sufficient
to detect estrogenic activity in the large scale tube assay (Figure 4.3.1, left side). Other yeast
assays require large volumes (5 liters per batch) and can be time-consuming (12 hours - 3 days)
(213). For smaller scale assays this protocol can be scaled down to a 96-well plate format in
which urine extracts could be tested (Figure 4.3.1, left side). However, it should be noted that the
plate format would likely require sample extraction adding sample preparation time to the
protocol. The use of a “plate” assay for the direct measure of estrogenic activity without urine
extraction was also tested to determine if 1 µl of urine was sufficient to give a signal. The logphase yeast were incubated with concentrated urine for 2 hour in a 30°C incubator with no
movement and the cells were further lysed and incubated with β-galactosidase substrate for 2
hours. Similar to the left side of Figure 4.3.1, the plate was then read in a luminometer machine.
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Figure 4.3.1 Schematic Representation of Yeast Bioassay Protocol.

88

Figure 4.3.1. Schematic Representation of Yeast bioassay protocol
An overnight culture was inoculated in 10 ml of SC-UW. The following day, it was diluted back
to an O.D.600 of 0.08 and allowed to reach logarithmic phase growth before the addition of urine
sample. The three trimesters can be assayed directly by mixing with concentrated yeast medium
and placed on the cells for 2 hours (left panel). 100 µl of the non-extracted sample is then
transferred to a 96-well plate, covered and incubated for 2 hours and analyzed with a microplate
luminometer. The concentrated samples can be examined similarly to the traditional method of a
yeast assay in which the minimal amount of 1 µl of urine required was tested (left panel). The
yeast cells are only treated with urine sample for 2 h and then incubated with 100 µl of βgalactosidase substrate for an additional 2 hours at room temperature and read in a microplate
luminometer.
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4.3.2 Human Urine Yeast Assay
To demonstrate that there is an increasing activity of estrogenic signal in our yeast cells,
we performed a hormone dose response with yeast only and increasing concentrations of 17βEstradiol diluted in ethanol in parallel to our yeast assay (Figure 4.3.2A). To assess whether the
direct measure of estrogenic activity in human urine was plausible, we performed the yeast assay
with human urine from pregnant females in their first, second, or third trimester. We decided to
use human urine from pregnant females based on evidence that correlates the increase in
estrogenic activity as the trimester’s progress (212). To control for hormone induction, we
charcoal-stripped all three trimesters and used them as our negative control. In Figure 4.3.2B, the
third trimester showed the highest amount of estrogenic activity in comparison to the first and
second. In addition, the CT-treated urine was successful and minimal amounts of estrogenic
activity were detected. Given the short amount of incubation time needed for the urine and yeast
cells, we sought to determine whether using a “plate” yeast assay in which 1 µl of urine could be
employed and tested for estrogenic activity (Figure 4.3.2C). Similarly to the direct measure of
urine in the yeast assay, we observed the trend of the highest estrogenic activity in the third
trimester. Although, the first and second trimester compared to the CT-urine treated did not
display a significant change. Thus, this data set is the first to show the direct measure of human
urine in the yeast bioassay and established that the assay is a valid means to be further
investigated.
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Figure 4.3.2 Yeast Bioassay is Applicable in Urine.
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Figure 4.3.2 Yeast Bioassay is Applicable in Urine
A. Representative dose response curve for typical estrogenic activity using 17β-Estradiol as the
ligand in yeast cells using the four-hour yeast bioassay. B. Urine samples taken from the three
trimesters were assayed directly and tested for estrogenic activity in yeast bioassay. Dextrantreated charcoal was compared to untreated urine. C. A non-direct way to measure estrogenic
activity was performed with dextran-treated charcoal and untreated urine as described in Figure
4.3.1, right side. All data points are averages of three independent replicates with error bars
representing standard deviation.
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4.3.3 Human Urine Yeast After Enzyme Pretreatment
Representative dose-response curves of typical estrogenic ligand, 17β-Estradiol, spiked
into the charcoal-treated 1st, 2nd and 3rd trimester urine is shown in Figure 4.3.3A. These data
demonstrate that the 17β-Estradiol dose-response performed in conjunction with the assay of
unknown samples can be performed drectly in the control urine and also validates the assay for
use in directly screening urine samples. Given that estrogenic metabolites are excreted in
conjugated form we sought to assess whether pretreatment with deconjugating enzymes would
improve the sensitivity and reliability of the assay. For a prototypical comparison, we pretreated
the urine with β-Glucuronidase and sulfatase enzymes for 30 minutes to assess liberated
hormones and increased activity. Untreated, CT-, and β-Glucuronidase and sulfatase-treated
urine was assessed using the yeast bioassay (Figure 4.3.3B). The measured estrogenic activity as
previously demonstrated had an increasing trend per trimester with untreated urine. The urine
treated with β-Glucuronidase and sulfatase exhibited an increase in activity. Interestingly, there
was a noticeable effect in the 1st trimester as there were more hormones liberated than in the rest.
Although the 2nd trimester had a slight increase as well, the trend similar to that found in
untreated urine remained. No significant change was observed in the 3rd trimester with treated vs
untreated urine. All three trimesters exhibited minimal estrogenic activity in the CT-urine
samples from all three trimesters. It is clear that addition of β-Glucuronidase and sulfatase
enzymes is not necessary to observe estrogenic activity, nor to observe the expected trend in the
data. While pretreatment with these enzymes increased the maximal level of estrogenic activity
detected, it did not change the conclusions that could be drawn from the data. Thus, the
pretreatment with deconjugating enzymes is likely unnecessary for comparison of estrogenic
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activity across samples, but may be desired if the goal is to assess total estrogenic activity from
both free and conjugated estrogens.
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Figure 4.3.3 Urine Treated with β-Glucuronidase and Sulfatase Enzymes
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Figure 4.3.3. Urine Treated with β-Glucuronidase and Sulfatase Enzymes
A. Representative 17β-Estradiol dose response curve in which the ligand solubilized with ethanol
vehicle was added straight to the wells containing either 1st, 2nd, or 3rd trimester CT-urine. B.
Urine samples taken from the 1st, 2nd, and 3rd trimester were either charcoal-treated or βGlucuronidase and sulfatase treated, and untreated samples were directly measured using the
yeast bioassay. The untreated and β-Glucuronidase and sulfatase treated urine were significantly
higher than the CT-treated urine. Each data point is an average of triplicates with error bars
representing standard deviation.
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4.4 Discussion
The four-hour recombinant yeast bioassay has been utilized for the direct measure of
environmental water, wastewater, and sediment samples in a time and cost-efficient manner. In
this chapter, we have validated the easy and sensitive method to detect estrogenic activity in
human pregnant urine. We observed the increasing estrogenic activity with the three different
trimesters, and the estrogens can be removed efficiently upon charcoal treatment. A limitation in
this study is that the urine was purchased and the way the urine was collected may not have been
properly controlled for. In addition, the trimesters are months long and there is no indication at
which time within the trimester the urine was collected. Thus, these studies did not aim to
determine the exact estrogenic activity present within the trimesters, but instead aimed to
demonstrate that the yeast-based assay could be used to directly assess estrogenic activity within
the urine. This assay will be a powerful tool for endocrine disruption studies in animal models
given the low volume of urine generated in mice and rats as compared to human samples.
Collectively, the data presented here demonstrate an inexpensive, short assay for use in screening
for estrogenic activity in urine that could be adapted to a high throughput format.
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Chapter 5: Conclusions
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5.1 SGTA is a Participant in the Early Complexes of the Chaperone-Mediated
Receptor Folding Pathway
The data presented in Chapter 2 provides the first evidence of a role for SGTA in the
chaperone-steroid hormone receptor complex. Similar to what was observed in previous reports,
SGTA binds to Hsp70 and Hsp90 (68, 105). We are the first to demonstrate direct interaction in
vitro and to determine binding affinities for the interactions between SGTA and Hsp70 or Hsp90
(Figure 2.3.1). Using isothermal titration calorimetry, we demonstrated that human recombinant
SGTA binds Hsp70 with an affinity of 6.1 µM and to Hsp90 with an affinity of 11.0 µM in vitro.
A co-immunoprecipitation performed in yeast lysates (Figure 2.3.1C) exhibited that the HisSgt2, SGTA’s yeast homologue, bound Hsp70, yet did not bind Hsp90ΔMEEVD, implying that
SGTA does not likely bind to Hsp90 within a cellular context. Moreover, in vitro PR
reconstitution assays demonstrated that SGTA is not a participant in the folding of the receptor to
the hormone-binding competent conformation in reticulocyte lysate. The data suggests that
SGTA can associate with chaperone complexes, although this is not due to the alteration of
receptor folding and hormone binding (Figure 2.3.2). In addition, deletion of the glutamine-rich
region at the carboxy-terminus of SGTA resulted in failure to abrogate AR function in yeast
when compared to full-length SGTA (Figure 2.3.4).
While it was clear that SGTA has a functional role in AR, GR, and PR signaling, the
exact functional domains and/or residues critical for this function were unknown. Thus, we
assessed SGTA truncation mutants to determine the contributions of the SGTA domains to
regulation of receptor activity. It is clear that the TPR domains, which are highly conserved, are
critical for Hsp binding and function. However, we sought to determine the contributions of the
Q-rich region in the C-terminus and the N-terminal dimerization domain. Our data demonstrate
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that the C-terminal Q-rich domain, but not the N-terminal dimerization domain, is critical for
receptor regulation (Figure 2.3.4). However, we make this conclusion with some caution given
that misfolding of the truncation mutants could also lead to a loss of activity. Further studies are
needed to firmly establish the importance of the Q-rich domain in the SGTA regulation of steroid
hormone receptor signaling. However, if verified this would suggest a unique mechanism for
SGTA given that it is the only TPR-containing cochaperone that utilizes a Q-rich domain. AR’s
structure is composed of four functional domains, and Buchanan et al hypothesized that SGTA
regulates through binding to the hinge region (69). However, if the truncation failed to abrogate
AR activity, perhaps SGTA regulates through the NTD with corepressors. It has been shown that
coactivators/repressors with a Q-rich region bind preferentially to DNA (214-216). It could be
possible that SGTA is interacting with other corepressors and influencing the AR-dependent
cistrome and transcriptome. This could also explain why SGTA can regulate GR and PR since
the NTD communicates with the DBD and is the most conserved region in the nuclear receptor
superfamily.

5.2 SGTA Interacts with and Antagonizes PRDX1 in AR Function
The fact that SGTA associates with Hsp70/90 complexes was well known and further
confirmed and quantitated by our laboratory (Chapter 2). Furthermore, yeast-two hybrid screens
have extensively contributed to the repertoire of binding partners of SGTA (Table 1). Thus, the
functional role for Hsp70, Hsp90, and viral proteins with SGTA has given SGTA a key role in
cellular processes (e.g. cell cycle progression and apoptosis). However, the role SGTA played in
a prostate cancer scenario with other binding partners was relatively unknown. Thus, we
employed a label-free quantitative proteomics approach using a 6X-His-FLAG-SGTA in LNCaP
PCA cells in an attempt to answer this question (Chapter 3). In agreement with studies conducted
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previously (105, 117), a 0.5% FDR hierarchical clustered analysis revealed that Hsp70 and
Hsp90 preferentially bind to SGTA (Figure 3.3.2 and Figure 3.3.3), thus, providing a confident
screen for unknown protein interactors with SGTA. Our results showed that a total of 31 proteins
preferentially bound SGTA in both biological replicates and the four technical replicates within
each biological replicate. Remarkably, a strong interaction appeared with the prey gene B2R4P2,
which encodes PRDX1. A cluster of ribosomal proteins was also present and observed in the
STRING network analysis (Figure 3.3.3). Ribosomal proteins can account for 30% of the cell’s
total mass and are critical for protein synthesis (217). However, due to their sticky nature, in
proteomics, ribosomal proteins are often considered false positives (218). Nevertheless, more
recently Hsp90 and Hsp70 were shown to interact with the intact ribosome and have been
demonstrated to be relevant in protein synthesis (219, 220). It is possible that SGTA could be a
participant in these mechanisms, and further validation of these proteins with SGTA would be
required to assess relevance.
The heat map generated for SGTA was validated with co-immunoprecipitation in LNCaP
cells, and an in vitro FLAG pull-down assay with human recombinant SGTA and PRDX1
(Figure 3.3.5). To assess whether this interaction was functionally relevant, we performed an
AR-mediated reporter assay with co-expression of SGTA and PRDX1. SGTA antagonizes
PRDX1 effects on AR in HeLa and 22RV1 SGTAKO cell lines (Figure 3.3.6). Interestingly,
PRDX1 up-regulated AR activity even in the absence of DHT in 22Rv1 cells (Figure 3.3.6B).
Given that 22RV1 cells have a truncated, constitutively active AR and are used as a model to
mimic CRPC, this might suggest that PRDX1 regulates AR through the N-terminus and could
have effects on the AR splice variants that can drive the hormone refractory state in CRPC.
Future studies are needed to further assess this observation. Future studies should assess this
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mechanism in a cell line in which SGTA and PRDX1 are both deleted, which would eliminate
endogenous PRDX1 activation and allow for us to better assess the functional interplay between
these two proteins. Experiments designed to determine if the catalytic function of PRDX1 is
involved with SGTA regulation are also warranted. If this were the case, this could be another
functional role for SGTA in cellular homeostasis.
Our data suggests that SGTA is a strong inhibitor of AR function and can antagonize
FKBP52 and PRDX1 (Figure 5.1.1). FKBP52 and PRDX1 are known to be strong positive
regulators of AR function. SGTA is expressed at low levels in LNCaP cells, and interestingly,
PRDX1 was found to be a positive regulator here. Thus, SGTA could be part of a functional
rheostat mechanism that works to maintain a balance between strong positive regulation of AR
activity by up-regulation of a negative regulatory factor. In prostate cancer this balance is upset
as FKBP52 and PRDX1 are found to be highly up-regulated whereas SGTA is found to be downregulated leading to hyperactivity of the AR signaling pathway, thereby promoting tumor growth
and progression.
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Figure 5.1.1 SGTA Portrays Antagonistic Effects on FKBP52 and PRDX1.
FKBP52 exerts a positive regulatory effect on AR, GR, and PR. PRDX1 up-regulates only AR in
prostate cancer cells. Thus far, our model suggests that SGTA can antagonize FKBP52 and
PRDX1 function in AR.
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5.3 The 4-Hour Yeast Bioassay is Valid for Testing Estrogenic Activity in Human Urine
The four-hour receptor-mediated reporter assay in yeast has been used extensively to
identify and characterize chaperone and cochaperone regulation of SHRs (185), screen
compounds (156), and assess estrogenic activity in wastewater (184) and sediment samples
(202). The data presented in Chapter 4 are the first to establish that the four-hour yeast bioassay
is applicable in testing human urine directly without urine extraction and concentration.
Remarkably, there was no toxicity observed in the yeast cells growing directly in the urine for
two hours (Figure 4.3.2). A hormone dose response (HDR) curve was generated directly in the
urine to ensure that hormone induction was present and was not influenced by the urine
treatment, which further validates our assay in assessing the increasing estrogenic activity within
the three trimesters from human urine. For yeast assay quality control, we tested the CT-treated
urine, which eliminated estrogenic activity. Thus, it is likely that the activity observed is due to
organic molecules present within the urine.
It has been documented that treating urine with β-Glucuronidase and sulfatase liberates
estrogens and other hormones, and is sufficient to increase sensitivity in screening estrogenic
activity (213). First, we assessed an HDR with CT-urine and observed an increase of estrogenic
activity as the dose increased (Figure 4.3.3A), thus, demonstrating that even with spiked CTurine, the yeast were responsive and displayed no toxicity. To test for liberated hormones, in
Figure 4.3.3B, we demonstrated that the treatment of urine with β-Glucuronidase and sulfatase
dramatically raised the yields of the activity in comparison to the untreated urine. The most
dramatic increase of liberated estrogens was in the first trimester of β-Glucuronidase and
sulfatase treated urine. Interestingly, the second and third trimester did not liberate as much
ligand as the first. All together, these assays provide a valid method for testing estrogenic
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activity in human urine. Although we are aware that handling the urine samples may increase
variability, our assay shows that human urine is not toxic to yeast cells and can be used to assess
estrogenic activity in human urine samples. Future studies should aim to fractionate the urine
samples coupled to mass spectrometry to identify the active metabolites within the urine.
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Glossary of Key Terms
AD- Alzheimer’s disease
ADT- Androgen deprivation therapy
AIS- Androgen insensitivity syndrome
AF-1- Activation function 1
AF-2- Activation function 2
AR- Androgen receptor
AR-V7- AR-splice variant 7
BAG- BCL-2 athanogene
BAG-1- BCL-2 athanogene 1
BAG-6- BCL-2 athanogene 6
BF-2 Binding function 2
CHIP- COOH terminus of the Hsp70-interacting protein
Co-IP- coimmunoprecipitation
COS-1- CV-1 in origin and carrying the SV40 genetic material
CKII- Creatine kinase II
CRPC- Castration resistant prostate cancer
CRISPR- Clustered regularly-interspaced short palindromic repeats
CSP- Cysteine string protein
CT- Charcoal treated
Cyp40- Cyclophilin 40 kDa
DBD- DNA binding domain
DHT- 5α-dihydrotestosterone
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DMEM- Dulbecco’s modified eagle medium
DMSO- Dimethyl sulfoxide
DOC- deoxycorticosterone
EDC- Endocrine disrupting compound
EDTA- ethylenediaminetetraacetic acid
E2- 17β-Estradiol
ER- Estrogen receptor
FASP- Filter assisted sample preparation
FDR- False discovery rate
FBS- Fetal bovine serum
FKBP51- FK506 Binding Protein 51
FKBP52- FK506 Binding Protein 51
GAPDH- glyceraldehyde-3-phosphate dehydrogenase
GCUNC-45- General cell UNC45
GET- Guided Entry of TA proteins
GFP- Green fluorescence protein
GO- Geneontology
GR- Glucocorticoid receptor
GST- Glutathione-S-transferase
HDR- Hormone dose response
HERV-K (HML-2)- Human endogenous retroviruses
HIP- Hsp interacting protein
HOP- Hsp organizing protein
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HPD- Histidine, proline, and aspartic acid amino acid residues
HRE- Hormone response element
HSF-1- Heat shock transcription factor 1
Hsp- Heat shock protein
Hsp40- Heat shock protein 40 kDa
Hsp70- Heat shock protein 70 kDa
Hsp90- Heat shock protein 90 kDa
IP- Immunoprecipitation
IL-6- Interleukin 6
LBD- Ligand binding domain
LC-MS/MS- Liquid chromatography- mass spectrometry/mass spectrometry
LNCaP- Lymph node derived from cancer patient
MAPK- Mitogen activated phosphokinase
MEM/EBSS- Minimal essential medium/ eagles essential salt solution
MPER- Mammalian protein extraction reagent
MR- Mineralocorticoid Receptor
NLS- Nuclear localization signal
NTD- Amino transactivation domain
NS1- Nonstructural protein 1
p23- Protein 23 kDa
PC3- AR-negative cell line
PCA- Prostate cancer
PCOS- Polycystic Ovary Syndrome
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PD- Proteome Discoverer
PI3K- Phosphatidyl inositol-3-kinase
PPIase- Peptidyl prolyl cis-trans isomerase
PP5- Serine/threonine protein phosphatase 5
PR- Progesterone Receptor
PRDX1- Peroxiredoxin 1
PRDX6- Peroxiredoxin 6
PSA- Prostate specific antigen
PVDF- Polyvinylidene fluoride
RL- Reticulocyte Lysate
RLU- Relative light units
RPMI- Roswell Park Memorial Institue
SARS-CoV7a- Severe acute respiratory syndrome coronavirus
SGTA- Small Glutamine Rich TPR-Containing Protein Alpha
SGTβ- Small Glutamine Rich TPR-Containing Protein Beta
SGTAKDHeLa- SGTA knockdown Henrietta Lacks cells
SGTAKOHeLa- SGTA knockout Henrietta Lacks cells
SGTAKO22RV1- SGTA knockout 22RV1 cells
SHR- Steroid hormone receptor
STAT3- Signal transducer and activator of transcription 3
STRING- Search Tool for the Retrieval of Interacting Genes/Proteins
SUMO- Small ubiquitin like modifier
TA- Tail anchored
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TPR- Tetratricopeptide repeat
TRC40- Transmembrane domain recognition complex of 40 kDa
UBP- U binding protein
UbE- Ubiquitin-dependent endocytosis
VpU- Viral protein U
WT- Wild type
Y2H- Yeast two-hybrid
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